

**CURRICULUM VITAE**  
Prepared February 2023

**DAVID HEALY, MD FRCPsych**  
**Professor of Psychiatry**  
**Founder and Chief Scientific Officer**  
**Centre for Data Based Medicine**

**E-Mail: David.Healy54@Gmail.com**

**Citizenship:** Republic of Ireland  
**Country of Residence:** Canada

**APPOINTMENTS**

|                  |  |
|------------------|--|
| July 2019 – 2022 | Professor, Dept of Family Medicine, McMaster University, Canada  |
| January 2014     | Professor of Psychiatry, Bangor University, UK   |
| November 2004    | Professor of Psychiatry, Cardiff University, UK  |
| March 2004       | Adjunct Professor in Centre for Social and Community Research<br>Murdoch University, Perth, March 2004 – February 2007   |
| April 2001/05    | Visiting Professor, University of Toronto<br>Faculty of Medicine   |
| Feb 1996         | Reader in Psychological Medicine<br>Division of Psychological Medicine,<br>University of Wales College of Medicine (UWCM).   |
| Feb 1992         | Director,<br>North Wales Department of Psychological Medicine (UWCM).  |
| Jan 1990         | Senior Lecturer in N Wales Dept of Psychological Medicine<br>Division of Psychological Medicine<br>University of Wales College of Medicine (UWCM),<br>& Honorary Consultant in Psychiatry, North Wales |

## **EDUCATION**

**Medical Education:** University College Dublin, 1973-1979, MB BCH BAO  
1st Medical Class Prize & Scholarship  
MD (PhD in US) awarded in December 1986

**Psychiatric Training:** Member Royal College of Psychiatrists - Spring 1985  
Fellow Royal College of Psychiatrists - Spring 1996

### **Post-Graduate Clinical Training:**

1. September 1980 – June 1984

I was a Senior House Officer based at the Psychiatric Unit in Galway University Hospital, primarily with Professor PA Carney, but also with Professor TJ Fahy, and Dr A Carroll (child psychiatry). The training included regular ward rounds, outpatient clinics, on-call duties, community outreach visits, delivery of electroconvulsive therapy (ECT), case conferences, and post-graduate education sessions.

This training was undertaken while I was also undertaking research for a doctoral thesis.

2. July 1984 – June 1985.

I was a Psychiatric Registrar with Dr G Mullet and Professor M Webb in St James Hospital Dublin as part of the St Patrick's Hospital psychiatric rotation. The training included routine ward rounds, outpatient clinics, on-call duties, community outreach, delivery of ECT, case conferences and post-graduate education sessions.

3. July 1985 - December 1985

This period was devoted to writing up my doctoral thesis but also included outpatient and on-call work in the Regional Hospital Galway..

4. January 1986 - March 1986

Psychiatric Registrar, St Mary's Hospital, Castlebar covering ward rounds, outpatient clinics, on-call duties, community outreach, and delivery of ECT.

5. April 1986 – July 1988

I was an Honorary Senior Registrar and Clinical Research Fellow on the East Anglian Rotational Training Scheme, based with Professor ES Paykel, and Drs J Dowson and GE Berrios at Addenbrooke's Hospital in Cambridge and Fulbourn Hospital in Fulbourn. My duties involved taking ward rounds, outpatient clinics, and on-call, covering general adult psychiatry. I was also involved in teaching medical students and psychiatric trainees both in Cambridge and the wider East Anglian region.

6. August 1988 – July 1989

I was a Senior Registrar in Psychogeriatric Psychiatry with Drs E Tyms and P Brook based at Fulbourn Hospital, Hinchingbrooke Hospital and centres in St Ives and St Neots, covering ward rounds, outpatient clinics, on-call duties and the delivery of ECT.

7. August 1989 – January 1990.

Senior Registrar in Helleston Hospital Norwich with Dr Daphne Rumball covering general adult psychiatry and substance misuse.

8. January 1990 – April 1990  
Locum consultant in Norwich covering Substance misuse and general adult psychiatry.

**Clinical Appointments:**

In 1990, I was appointed to a joint academic/clinical post in the psychiatry in the University of Wales and the then North Wales Health Authority, now the Betsi Cadwaladr University Health Board.

My clinical duties from May 1990 to the present have involved:

- Inpatient cover in the Hergest Unit, a District General Hospital, mental health unit.
- Outpatient and community cover with the Roslin Community Mental Health Team in Llandudno
- Delivery of an ECT service
- Delivery of a specialist psychopharmacology consultation service
- Liaison cover for Ysbyty Gwynedd District General Hospital
- On-call cover for North West Wales

I was registered with the Irish Medical Council from July 1979 to June 1986.

I was registered with the General Medical Council in Britain from April 1986 to the present.

I have had no sick leave or periods of absence from July 1979 to the present.

Since February 2020, I have been working with the Guelph Family Health Team and the Welland-McMaster Family Health Team.

I am now registered with the College of Physicians and Surgeons of Ontario. .

## **ROYAL COLLEGE of PSYCHIATRISTS ACTIVITIES**

Senior Organiser MRCPsych exam 1991-1993

Scheme Organiser for Senior/Specialist Registrars 1992-1997.

MRCPsych Part I examiner

College representative on Appointment Committees

Assessor of Membership Research Projects

## **RESEARCH TRAINING**

MD thesis commenced August 1980,

Supervised by Brian Leonard, Prof. of Pharmacology, U College, Galway

& Directed by Professor T B Counihan, Dept of Medicine, U College, Dublin.

Thesis "Biochemical Correlates of Depression" submitted Dec 1985

A study of platelet 5HT uptake and 5HT induced aggregation responses, platelet alpha adrenoceptor binding and lymphocyte beta adrenoceptor binding in depression.

Clinical Research Associate - Dept of Psychiatry, Cambridge, April 86 - March 88

Funded by a Wellcome Trust Major Grant Award: Biological Markers in Depression.

My Cambridge research also included work on concentration & memory in depression

## **FOUNDATIONS**

Founder and Board Member Centre for Data Based Medicine: 2010 to present

Board Member Foundation for Excellence in Mental Health: 2010 to present

Founder and Board member Data Based Medicine Limited: 2010 to present

Data Based Medicine aims at facilitating patient adverse event reporting and provision of state of the art consumer information using website technology RxISK.org. This is a multinational collaboration with multidisciplinary input across primary care, general medicine, psychiatry, pharmacology, pharmaco-epidemiology, genetics and anthropology as well as across the primary-secondary care interface and is linked to the WHO Uppsala Monitoring Centre for pharmacovigilance. The platform will provide opportunities for epidemiological investigations, genetic studies, drug discovery, and a range of opportunities to explore sociological/ anthropological issues in qualitative studies and the aim is to have the Centre for Data Based Medicine as a self funding institute with links to a major academic institution.

## RESEARCH GRANTS

1. Research Fellowship Dept of Pharmacology, U Coll Galway, 1980-82.
2. MRC Ireland Research Grant to investigate circadian variations in biological markers in depression, 1982-1984.
3. Research Fellow 1986 to 1988; Wellcome Trust Major Grant Award held by Prof E S Paykel in Cambridge.
4. Grant holder from the Welsh Scheme for Health & Social Services Research for a Cognitive Therapy of Delusions, Jan 1992 to Jan 1994, £43,000.
5. Grant holder Clwyd H.A.: Cognitive Therapy of Delusions; £50,000.
6. Grant holder Wellcome Trust for equipment for investigating the cognitive neuropsychology of neuroleptic drugs. £5,000.
7. Grant holder SmithKline Beecham for work on the cognitive neuropsychology of drugs active on the 5HT system. £50,000.
8. Clinical trial of a 5HT-1A agonist in depression, Duphar, £25,000.
9. Co-Holder of a MRC/Welsh Office/NW Reg H Authority Grant with R Bentall, R Stevenson and J Day (U of Liverpool), A Rogers (U of Manchester) G9322371, A multidisciplinary study of the management of neuroleptic medication in schizophrenia: educational and collaborative approaches. 1994-1998, £300,000.
10. Collaborator with M Jones and P Michael (UWB) on a Wellcome Trust Grant to research the history of the North Wales Hospital 1992-1995.
11. Co-holder Wellcome Trust Grant with Dr M Fraser and Professor N Rose, Dept of Sociology, Goldsmith's College London, Ethical Aspects of Psychiatric Drug Development, £88,000. Grant no. 065209/Z/01/Z/CM/CD/SW, 2001-2004.
12. Co-holder with Professor E Shorter, Dept of History, U of Toronto, of a Canadian Institutes of Health Research grant 116654: "The renewal of the pharmacopoeia for mood and anxiety 1966-2003", \$312,000: 1.10.03 to 30.09.06.
13. Coholder with Mark Rapley: Medicating the Unruly Child: A genealogy of ADHD, = \$AUS18, 500, MU Research Excellence Grants Scheme, no #.
14. Coholder with F Bayliss, J Downey et al States of Mind: Emerging issues in Neuroethics, Canadian Institutes of Health Research. Spring 2006, NNF 80045, Can \$1,376,500.
15. Holder grant on Toxoplasmosis infection in psychosis from Stanley Medical Research Foundation, granted Summer 2007, \$300,000.
16. Co-Holder with Dr S Linden, War trauma and mental illness: Psychopathology and the natural histories of patients admitted to the North Wales Asylum during WWI. Reference: SG090329
17. Data Based Medicine Development Funds: \$500,000.

## **MEMBERSHIP OF SOCIETIES**

Royal College of Psychiatrists - 1985.

Fellow - 1996.

British Association of Psychopharmacology -

Council Member & Hon Asst Secretary, 1989-1992

Secretary 1992-1995

Member of the Association of European Psychiatrists.

Member of European College of Neuropsychopharmacology

Fellow of Collegium Internationale Neuropsychopharmacologium

Member of the History Group Royal College of Psychiatrists

Member of the European Association for the History of Psychiatry

Member of the History Section of the World Psychiatric Association

Secretary 2009 ongoing.

Member of the European Society for Chronobiology

Member Advisory Board of European College of Study Methods in Clinical Trials

Member of ECNP working party for the History of Neuropsychopharmacology

Associate of BIOS: Centre for the study of Bioscience, Biomedicine, Biotechnology and Society at the London School of Economics and Political Science

## **DISTINCTIONS**

- First Mental Health Foundation Essay Prize for 1988
- Awarded a CINP Rafaelson Scholar Award in 1988
- Keynote Speaker at 30<sup>th</sup> Annual RANZCP Meeting - May 1995.
- Visiting Lecturer at the Clarke Institute of Psychiatry & Guest Lecturer on the History of Medicine Program, Univ. of Toronto, October 1995.
- Chair Wellcome Trust Witness Seminar March 1997.
- Guest Lecturer. 7<sup>th</sup> Japanese Clin Neuropharmacology Assoc. Tokyo, Nov 1997.
- Invited Lecture – American Psychopathological Association March 1999.
- Annual Raths-Steiger Lecture, Collegium Helveticum, ETH Zurich June 1999.
- Distinguished Guest Lecture, Dept of Psychiatry, Oslo, March 2000.
- Eric T Carlsson Memorial Grand Rounds, Cornell University, N York, Dec 2000
- Annual MIND-Institute of Psychiatry Lecture, February 2002.
- Bartlett Visiting Professorship, U of Rochester, N York, Nov 2003.
- Studium Generale Lecture Groningen April 2005
- Chancellor's Distinguished Guest Lecture, Louisiana State University Oct 2005
- ACNP Oakley Ray Annual Lecture on History of Psychopharmacology 2008
- Studium Generale Lecture Gent, February 2012
- Willis Cunningham Lecture in Law & Medicine Queens' University Kingston, Sept 2016

## **CLINICAL WORK**

I have practised for 3 decades as a consultant psychiatrist in North Wales. My clinical work has involved the full gamut of clinical activities from in-patient care to out-patient and community care, covering all mental health conditions including organic, psychotic, drug dependence and personality based conditions, in all ages from centenarians to adolescents.

My training was in urban settings – Dublin, Cambridge, Galway. My clinical practice in North Wales has been largely rural. North West Wales, where I have worked, is among the poorest and most deprived regions of the UK.

On arriving in North Wales, I established multidisciplinary working in a sectorized service, with a clinical service that from the start had service users copied into all correspondence on them. This has been subject to a number of studies and has given rise to articles listed in the reference section. It has been highly praised by a number of service auditors and others.

This practice has been mostly run from primary rather than secondary care settings.

From 1997, I was the lead consultant for ECT in North-West Wales

From 2002 to the present, I have had clinical sessions devoted to the development of a liaison service with the general medical services in Bangor, covering all aspects of mental health presentations in general medical settings.

Through 1990-94, I was Chairman of the North West Wales group of psychiatric consultants. During this time, the psychiatric services moved from acute to community unit management and the North Wales psychiatric services adopted Trust status. By virtue of my position, I was centrally involved in developments.

At a Directorate level:

From 2002 I have been the Chair of the Local Consultant group.

I chair the Mental Health Clinical Governance Group.

From 2002 to 2007 I was deputy clinical director

On behalf of the North West Wales Trust:

I sit on the Research Committee,

& on the Clinical School Development Committee

& I chair the Research Governance Review Committee;

This latter committee scrutinizes research for compliance with regulations such as the ionizing radiation regulations, human tissue act, capacity and consent, and for cost implications to the clinical service.

My clinical and academic input has been regularly cited as one reason why North West Wales had all substantive and training posts filled until recently, and why morale was particularly good in this service. There has since been a set of mergers and change in management approach that has probably taught me more in the last 3 years than I learnt in the previous 3 decades.

## **BOOKS**

**1. THE SUSPENDED REVOLUTION**  
**Psychiatry and Psychotherapy Re-examined**  
Faber & Faber, January 1990

**2. IMAGES OF TRAUMA**  
**From Hysteria to Post-traumatic Stress Disorder**  
Faber & Faber, March 1993

**3. PSYCHIATRIC DRUGS: EXPLAINED.**  
Mosby Yearbooks Ltd, March 1993  
Second Edition Harcourt Brace & Jovanovitch Winter 1996  
Third Edition Churchill Livingstone 2001  
Fourth Edition Elsevier Churchill Livingstone 2005  
Fifth Edition 2008.  
Japanese & French Translations 2009  
Chinese Translation 2015  
Sixth Edition 2016

**4. PSYCHOTROPIC DRUG DEVELOPMENT:**  
**Social, Economic and Pharmacological Aspects**  
A British Association for Psychopharmacology Monograph  
Chapman and Hall, Spring 1996  
Co-Editors: D Healy, D Doogan

**5. THE PSYCHOPHARMACOLOGISTS**  
Chapman & Hall, London, 1996  
Second Edition, Arnold, London, 2002

**6. THE ANTIDEPRESSANT ERA**  
Harvard University Press, Cambridge Mass, 1997  
Paperback Edition 1999  
French Translation – Le Temps des Antidepressseurs, 2002.  
Japanese Translation 2003

**7. THE PSYCHOPHARMACOLOGISTS (Vol 2)**  
Chapman & Hall, London, 1998  
Second Edition, Arnold, London 1999.

**8. THE PSYCHOPHARMACOLOGISTS (Vol 3)**  
Arnold, London (2000)  
With a reissue of Volumes 1 & 2.

**9. THE RISE OF PSYCHOPHARMACOLOGY& THE STORY OF THE CINP**  
Animula, 1998  
Co-Editors: T Ban, D Healy, E Shorter



**10. TEN YEARS THAT CHANGED THE FACE OF MENTAL ILLNESS  
(LES DIX ANS QUI ONT CHANGÉ LA FOLIE)**

Martin Dunitz, London 1999

Jean Thuillier

Translated from the French by Gordon Hickish & David Healy

**11. DIFFERENTIAL EFFECTS of The ANTIDEPRESSANTS**

Leonard BE, Healy D (1999).

Martin Dunitz, London.

British Medical Association Book Prize;

Translated into Spanish (2000).

**12. THE TRIUMPH OF PSYCHOPHARMACOLOGY AND THE CINP.**

Ed Ban T, Healy D, Shorter (2000).

Animula, Budapest.

**13. THE CREATION OF PSYCHOPHARMACOLOGY**

Harvard University Press,

Cambridge Mass 2002.

Paperback Edition, 2004

**14. FROM PSYCHOPHARMACOLOGY TO NEUROPSYCHOPHARMACOLOGY  
& THE STORY OF THE CINP**

Ed Ban T, Healy D, Shorter E (2002)

Animula, Budapest

**15. LET THEM EAT PROZAC**

**David Healy (2003)**

James Lorimer, Toronto

With linked website [www.healyprozac.com](http://www.healyprozac.com)

**Second Edition New York University Press (2004)**

**Japanese Translation 2005**

**Paperback Edition 2006**

**16. CLINICAL PSYCHIATRY in EUROPE**

**An Historical Perspective**

**from Selected Papers by Pierre Deniker**

**Translated by David Healy & Alden Press (2004)**

Royal Society of Medicine Press, London

**17. EUROPEAN CLINICAL PSYCHIATRY**

**An Historical Perspective**

**from Selected Scientific Papers by Pierre Deniker**

**Translated by David Healy & Alden Press (2007)**

Pierre Deniker Association, [www.association-pierre-deniker.org](http://www.association-pierre-deniker.org) Paris

**18. REFLECTIONS ON TWENTIETH CENTURY PSYCHOPHARMACOLOGY**

**Ed T Ban, D Healy, E Shorter**  
Animula Press, Budapest, 2004

**19. SHOCK THERAPY**

**A History of Electroconvulsive Treatment in Mental Illness**

**E Shorter and D Healy**  
Rutgers University Press  
University of Toronto Press  
September 2007

**20. MANIA**

**A Short History of Bipolar Disorder**

**Johns Hopkins University Press**  
Spring 2008  
Paperback 2010

**21. TRAITÉ MÉDICO-PHILOSOPHIQUE SUR L'ALIÉNATION MENTALE**

**Philippe Pinel**  
Translated G Hickish, D Healy, L Charland  
J Wiley & Sons 2008

**22. PHARMAGEDDON**

**University of California Press**  
Spring 2012  
Paperback 2013  
Japanese Translation 2015  
Italian Translation 2016

**23. THE DECAPITATION OF CARE**

**A short history of the rise and fall of Healthcare**

**La Santé décapitée**

**Brève histoire de l'avènement et de la chute du système de soins**

**La decapitation del cuidado**

**Una breve historia del auge y caída de la atención médica**

**La Sanita Decapita**

**Breve storia dell'ascesa e del declina della cura mediche**

**Samizdat – Health Writers Cooperative**  
Toronto Ontario Spring 2020.

**24. CHILDREN OF THE CURE**

**Missing Data, Lost Lives and Antidepressants**  
**D Healy, J Le Noury, J Wood**

**Samizdat – Health Writers’ Cooperative  
Toronto Ontario, Summer 2020**

**25. SHIPWRECK OF THE SINGULAR  
Healthcare’s Castaways  
Healy D**

**Samizdat – Health Writers’ Cooperative  
Toronto Ontario, Spring 2021**

**El Naufragio de lo Singular  
Trans A Oncina & M Casanas**

**Samizdat – Health Writers’ Cooperative  
Toronto Ontario, Autumn 2021**

**26. WE DON’T CARE, YOU DON’T MATTER  
Dilemmas of Healthcare Paternalism**

**27. THE MADNESS OF NORTH WALES**

## PEER- REVIEWED JOURNAL PUBLICATIONS

1. Healy D, Dunne M, Duignan J & Heffernan S J (1980). The use of ultrasonography in the diagnosis of retroperitoneal abscesses of the appendix. *Irish J Med Sci*, 149, 479.
2. Healy D, Carney PA & Leonard BE (1983). Monoamine- related markers of depression: change following treatment. *Journal of Psychiatric Research*, 17, 251-260.
3. Carney P A, Healy D, Leonard B E (1984). A double-blind study to compare trazodone with amitriptyline in depressed patients. *Psychopathology* 17, supp 2, 37-38.
4. Healy, D, Carney, P A & Leonard, B E (1984). Biochemical correlates of antidepressant response. *Psychopathology*, 17, supp 2, 82-87.
5. Healy, D, Carney, P A & Leonard, B E (1984). 5HT induced platelet aggregation, a useful clinical index in depression? *British J Clinical Pharmacology*, 17, 202-203.
6. Healy D & Egan E (1984). Centrifugal and anticoagulant induced variations on platelet rich plasma and their influence on platelet aggregation. *Scand J Haematol*, 32, 452-456.
7. Healy D, O'Halloran A, Carney PA & Leonard, BE (1985). Peripheral adrenoceptors and serotonin receptors: changes associated with response to treatment with trazodone or amitriptyline. *Journal of Affective Disorders*, 9, 285-296.
8. Healy D, O'Halloran A, Carney PA & Leonard BE (1986). Normal and abnormal variation in platelet 5HT uptake in control and depressed patients. *Journal of Psychiatric Research*, 20, 345-354.
9. Healy D, O'Halloran A, Carney PA & Leonard BE (1986). Platelet 5HT uptake in delusional and nondelusional depression. *J Affective Disorders*, 10, 233-239.
10. Healy D, O'Halloran A & Leonard B E (1986). Increases in platelet 5HT uptake rates following treatment with "uptake inhibiting drugs". *Int Clin Psychopharmacol* 1, 332-339.
11. Healy D (1986). Platelet monoamine uptake in depression: both chicken and egg deserve attention. *Human Psychopharmacology* 1, 48-49.
12. Healy D & Leonard BE (1987). Monoamine transport in depression: kinetics and dynamics. *Journal of Affective Disorders* 12: 91-105.
13. Healy D (1987). The structure of psychopharmacological revolutions. *Psychiatric Developments*, 5, 349-376.
14. Healy D (1987). Rhythm and Blues: neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders. *Psychopharmacology*: 93, 271-285.
15. Healy D (1987). The comparative psychopathology of animal and human affective disorders. *Journal of Psychopharmacology*, 1, 193-210.

16. Healy D & Williams JMG (1988). Dysrhythmia, dysphoria and depression; the interaction of circadian dysrhythmia and learned helplessness in the pathogenesis of depression. *Psychological Bulletin* 103: 163-210.
17. Healy D (1988). Neuropsychopharmacology - gazing into the crystal ball; a reply to Arvid Carlsson. *Human Psychopharmacology*, 3, 221-223.
18. Healy D & Williams JMG (1989). Moods, misattributions and mania: an interaction of cognitive and neurobiological factors in the pathogenesis of mania. *Psychiatric Developments*, 7, 49-70.
19. Healy D (1989). Neuroleptics and psychic indifference. *J Royal Society of Medicine*, 82, 615-619.
20. Williams JMG, Healy D, Teasdale J, White W, Paykel ES (1990). Dysfunctional attitudes and vulnerability to persistent depression. *Psychological Medicine*, 20, 375-381.
21. Healy D, Waterhouse JM (1990). The circadian system and affective disorders: clocks and rhythms. With commentary by T Wehr, *A Lewy Chronobiology International*, 7, 5-24.
22. Healy D (1990). Schizophrenia: basic, release, reactive and defect processes. *Human Psychopharmacology*, 5, 105-122.
23. Watts FN, Dalgleish T, Bourke P, Healy D (1990). Memory deficit in clinical depression: processing resources and structure of material. *Psychological Medicine*, 20, 345-349.
24. Healy, D, Theodorou, A, Whitehouse, A M, White, W, Wilton- Cox, H, Lawrence, K M, Kerry, S, Horton, R W, Paykel, E S (1990). Tritiated imipramine binding to previously frozen platelet membranes from depressed patients before and after treatment. *British Journal of Psychiatry* 157, 208-218.
25. Healy D, Paykel ES, White W, Whitehouse AM, Wilton-Cox H, Johnson T, Lawrence KM, Horton RW (1991). Platelet 3H Imipramine and alpha 2 adrenoceptor binding in normal subjects taking desipramine. *Neuropsychopharmacology* 4, 117-124.
26. Healy, D, (1990). The psychopharmacological era: notes toward a history. *Journal of Psychopharmacology* 4, 152-167.
27. Healy, D & Waterhouse J M (1991). Reactive rhythms and endogenous clocks: a shift work model of affective disorders. *Psychological Medicine* 21, 557-564.
28. Healy, D, Paykel, E S, Whitehouse, A M, White W, Ashby M, Brown M, Theodorou A E, Lawrence, K M, Horton, R W (1992). Plasma noradrenaline, adrenaline and DHPG responses to clonidine in control and depressed subjects. *Human Psychopharmacology* 7, 167-174.
29. Healy, D, Paykel, E S, White, W, Whitehouse, A M, Wilton- Cox, H, Theodorou A E, Lawrence, K M, Horton, R W (1991). Acid alpha-1 glycoprotein in eating disorders and depression. *Journal of Affective Disorders* 22, 13-20.

30. Theodorou A E, Lawrence K M, Healy, D, Whitehouse, A M, White W, Wilton-Cox, H, Kerry S M, Horton, R W Paykel E S (1991). Platelet alpha-2-adrenoceptors defined with agonist and antagonist ligands in depressed patients prior to and following treatment. *Journal of Affective Disorders* 23; 99-106.
31. Healy D (1991). The marketing of 5HT: anxiety or depression. *British J of Psychiatry*, 158, 737-742.
32. Healy D (1991). What do 5HT reuptake inhibitors do in obsessive-compulsive disorder. *Human Psychopharmacology*, 6, 325-328.
33. Creaney W, Murray I, Healy D (1991). Antidepressant induced suicidal ideation. *Human Psychopharmacology*, 6, 329-332.
34. Healy D (1991). D-1 and D-2 and D-3. *British J of Psychiatry* 159, 319-324.
35. Healy D (1991). The ethics of psychopharmacology. *Changes*, 9, 234-247.
36. Healy D (1991). Alprazolam and panic disorder. *Psychiatric Bulletin* 15, 682-683.
37. Browne I & Healy D (1992). In Conversation with Ivor Browne. *Psychiatric Bulletin* 16, 1-9.
38. McGrath D & Healy D (1992). In Conversation with Des McGrath. *Psychiatric Bulletin* 16, 129-137.
39. Katona C L E, Healy D, Paykel E S, Theodorou A E, Lawrence K M, Whitehouse A M, White W, Horton R W (1993). Growth hormone and physiological responses to clonidine in depression. *Psychological Medicine* 23, 57-63.
40. Healy D (1993). Psychopharmacology and the ethics of resource allocation. *British Journal of Psychiatry* 162; 23-29.
41. Healy D (1992). Altered states of consciousness: Phenomenology and pharmacology. *Journal of Psychopharmacology* 6, 425- 435.
42. Healy D (1993). One hundred years of psychopharmacology. *Journal of Psychopharmacology* 7, 207-214.
43. Healy D, Minors D, Waterhouse J M (1993). Shiftwork, helplessness and depression. *Journal of Affective Disorders* 29, 17- 25.
44. Moore J N P, Healy D, (1993). Interview with Norman Moore. *Irish Bulletin of Psychiatry* 1, 7-16.
45. Healy D (1993). 5HT and physical illness. *J of Psychopharmacology* 7, S1, pp 107-111.
46. Beaumont G, Healy D (1993). The place of clomipramine in the history of psychopharmacology. *Journal of Psychopharmacology* 7, 378-388.

47. Minors D, Healy D, Waterhouse J M (1994). The attitudes and general health of student nurses before and immediately after their first eight weeks of nightwork. *Ergonomics* 37, 1355-1362.
48. Sandler M, Healy D (1994). The Place of Chemical Pathology in the development of Psychopharmacology. *J of Psychopharmacology* 8, 124-133.
49. Watson F L, Pasteur M A, Healy D, Hughes E A (1994). Nine Parallel versions of four memory tests: An assessment of form equivalence and the effects of practice on performance. *Human Psychopharmacology* 9, 51-61.
50. Healy D (1994). The fluoxetine and suicide controversy. *CNS Drugs* 1 223-231.
51. Claridge G, Healy D (1994). The psychopharmacology of individual differences. *Human Psychopharmacology* 9, 285-298.
52. Wheatley D, Healy (1994). The foundation of the British Association for Psychopharmacology. *J Psychopharmacology* 8, 268-278.
53. Healy D, Waterhouse J M (1995). The circadian system and the therapeutics of the affective disorders. *Pharmacology and Therapeutics* 65, 241-263.
54. Fear C, Sharp H, Healy D (1995). Obsessive-compulsive disorder: Notes on its History and Nosology. *Journal of Serotonin Research* 1, Suppl 1, 1-18.
55. Fitzgerald K, Healy D (1995). Dystonias and dyskinesias of the jaw associated with the use of SSRIs. *Human Psychopharmacology* 10, 215-220.
56. Fear C, Sharp H, Healy D (1996). Cognitive processes in Delusional Disorders. *Brit J Psychiatry* 168, 61-67.
57. Healy D (1995). Social Phobia. *Primary Care Psychiatry* 1, 31-38.
58. Fitzgerald K, Williams B, Healy D (1997). Shared Care? Some effects of patient access to medical communications. *Journal of Mental Health* 6, 37-46.
59. Sharp H M, Fear C F, Williams, J M G, Healy D, Lowe C F, Yeadon H, Holden R (1996). Delusional phenomenology: Dimensions of change. *Behaviour Research and Therapy* 34, 123-142.
60. Minors D S, Pirmohamed J, Williams G, Edwards R, Healy D, Waterhouse J. (1995). Circadian rhythms of activity and rectal temperature at home and in hospital: the effects of lifestyle. *Chronobiology International* 12, 199-205.
61. Richter D, Healy D (1995). The origins of mental health-oriented neuroscience in Britain. *Journal of Psychopharmacology* 9, 392-399.
62. Adeniran R, Healy D, Sharp HM, Williams J M G Minors D S, Waterhouse J M (1996). Interpersonal sensitivity predicts depressive symptom response to the circadian rhythm disruption of night work. *Psychological Medicine* 26, 1211-1221.

63. Harborne G C, Watson F L, Healy D, Groves L (1996). The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. *Journal of Psychopharmacology* 10, 134-140.
64. Rees W L, Healy D (1997). The Place of Clinical Trials in the Evolution of Psychopharmacology. *History of Psychiatry*, 8, 1-20.
65. Fear C, Healy D (1997). Probabilistic reasoning in obsessive-compulsive and delusional disorders. *Psychological Medicine* 27, 199-208.
66. Fear C F, Healy D (1996). The use of the Emotional Stroop Test to assess neuroleptic activity. *Human Psychopharmacology* 11, 373-377.
67. Sharp H, Fear C F, Healy D (1997). Attributional style and delusions: An investigation based on delusional content. *European Psychiatry* 12, 1-7.
68. Sharp H M, Healy D, Fear C F (1998). Symptoms or side-effects? Methodological hazards and therapeutic principles. *Human Psychopharmacology* 13, 467-475.
69. Healy D (1998). Meta-analysis of trials comparing antidepressants and active placebos. *British Journal of Psychiatry* 172, 232-234.
70. Fear CF, McMonagle T, Healy D (1998). Delusional Disorders. Boundaries of a Concept. *European Psychiatry* 13, 210-218 (Comment by P Pichot and H-J Moller).
71. Healy D, Farquhar G (1998). The immediate effects of droperidol. *Human Psychopharmacology* 13, 113-120.
72. Williams B, Coyle J, Healy D (1998). The meaning of patient satisfaction. An explanation of high reported levels. *Social Science & Medicine* 47, 1351-1360.
73. Rogers A, Day JC, Williams B, Randall F, Wood P, Healy D, Bentall RP (1998). The meaning and management of neuroleptic medication; A study of patients with schizophrenia. *Social Science & Medicine* 47, 1313-1323.
74. Healy D, Mc Monagle TM (1997). Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. *J Psychopharmacology* 11, S25-S31.
75. Healy D, Nutt D (1997). British Association for Psychopharmacology Consensus on Statement on Childhood and Learning Disabilities Psychopharmacology. *J Psychopharmacology* 11, 291-294.
76. Tranter R, Healy D (1998). Neuroleptic discontinuation syndromes. *Journal of Psychopharmacology* 12, 306-311.
77. Healy D, Savage M (1998). Reserpine Exhumed. *British J Psychiatry* 172, 376-378.
78. Healy D, Langmaak C, Savage M (1999). Suicide in the Course of the Treatment of Depression. *Journal of Psychopharmacology* 13, 94-99.



79. Healy D (1998). Reboxetine, fluoxetine and social functioning as an outcome measure in antidepressant trials: implications. *Primary Care Psychiatry* 4, 81-89.
80. Healy D, Nutt D (1998). Prescriptions, licenses and evidence. *Psychiatric Bulletin* 22, 680-684.
81. Healy D, Tranter R (1999). Pharmacologic Stress Diathesis Syndromes. *J Psychopharmacology* 13, 287-290; Comments by H Ashton, A Young and N Ferrier, R Baldessarini, A Viguera and L Tondo, L Hollister, P Haddad and I Anderson, P Tyrer, pp 291-298 & Reply by Healy D & Tranter R – In the shadow of the benzodiazepines p 299.
82. Healy D (1999). Guest Editorial: A Failure to Warn. *International Journal of Risk & Safety in Medicine* 12, 151-156.
83. Healy D (1999). Reboxetine's effects on a social adaptation self-evaluation scale. *Acta Psychiatrica Scandinavica* 101, suppl 402, 45-51.
84. Healy D (1998). Pioneers in Psychopharmacology. *International Journal of Neuropsychopharmacology* 1, 191-194.
85. Healy D, Healy H (1998). The clinical pharmacological profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing? *J Affective Disorders* 51, 313-322.
86. Healy D (1999). The Three Faces of the Antidepressants. Critical Comments on the Clinical-Economic Framework of Diagnosis. *J Nervous & Mental Disease* 187, 174-180.
87. Healy D (1999). Antidepressant psychopharmacotherapy: at the crossroads. *International Journal of Psychiatry in Clinical Practice* 3, S9-S15.
88. Healy D (1999). Clinical trials and legal jeopardy. *Bulletin of Medical Ethics* 153, 13-18.
89. Fear C F, Sharp H M, Healy D (2000). Obsessive-compulsive disorder with delusions. *Psychopathology* 33, 55-61.
90. Healy D (2000). Some continuities and discontinuities in the history of the physical therapies before and after chlorpromazine. *History of Psychiatry* 11, 393-412.
91. Healy D (2000). A Dance to the Music of the Century. *Psychiatric Bulletin* 24, 1-3.
92. Healy D (2000). Good Science or Good Business? *Hastings Center Report* 30, 19-23. One of a series of 5 articles on aspects of the Prozac phenomenon with Carl Elliott, Peter Kramer, James Edwards and David DeGrazia.  
  
Republished in *Zlatna Greda* 14, pp 6-9, with commentary on the circumstances surrounding publication.
93. Healy D (2000). The case for an individual approach to the treatment of depression. *Journal of Clinical Psychiatry* 61, supplement 6, 24-28.

94. Healy D (2000). The assessment of outcome in depression. Measures of social functioning. *Reviews in Contemporary Pharmacotherapy* 11, 295-301.
95. Healy D (2000). Emergence of antidepressant induced suicidality. *Primary Care Psychiatry* 6, 23-28.
96. Healy D (2000). Pioneers in Psychopharmacology II. *Int J Neuropsychopharmacology* 3, 351-354.
97. Healy D (2001). Evidence biased psychiatry. *Psychiatric Bulletin* 25, 290-291.
98. Healy D, Savage M, Michael P, Harris M, Hirst D, Carter M, Cattell D, McMonagle T, Sohler N, Susser E (2001). Psychiatric bed utilisation: 1896 and 1996 compared. *Psychological Medicine* 31, 779-790.
99. Williams B, Healy D (2001). Perceptions of illness causation among new referrals to a community mental health team: "explanatory model" or "exploratory map". *Social Science & Medicine* 53, 465-476.
100. Boardman A, Healy D (2001). Modeling suicide risk in affective disorders. *European Psychiatry* 16, 400-405.
101. Williams B, Healy D (2001). Development of an explanatory model for "minor" mental health problems. *Journal of Advanced Nursing* 35, 108-116.
102. Healy D (2001). The dilemmas posed by new and fashionable treatments. *Advances in Psychiatric Therapy* 7, 322-327.
103. Healy D (2001). Psychopharmacology and the Government of the Self. A) Nature, Medicine, Website publication complete with slides, 28<sup>th</sup> June.
104. B) This has also appeared on AcademyAnalyticArts.org.
105. C) The has been translated as Psicofarmacologia y dominacion del ego, and appeared complete with slides in the periodical La Insignia, at [www.insignia.org/2003/enero/cyt\\_001.htm](http://www.insignia.org/2003/enero/cyt_001.htm)
106. D) Also published in The Rights Tenet, Spring 2002, pages 6-20 &
107. E) In Misuzu (Japanese) in November 2004, pp 18-32.
108. G) La Psychopharmacologie et le Gouvernement de Soi. In *Psythère. Revue de Psychiatrie*. [www.psythere.free.fr//article.php?id\\_article=39](http://www.psythere.free.fr//article.php?id_article=39) posted 15/06/2005.
109. F) Trajectory in Psychopharmacology: The role of the clinician and industry. *Indian J Psychiatry* 2003, 45, 49-56, Comment H Meltzer p 57 and J Kane p 58.
110. Tranter R, Healy H, Cattell D, Healy D (2002). Functional variations in agents differentially selective to monoaminergic systems. *Psychological Medicine* 32, 517-524.

111. Healy D (2002). Conflicting interests in Toronto. Anatomy of a Controversy at the Interface of Academia and Industry. *Perspectives in Biol & Medicine* 45, 250-263.
112. Herxheimer A, Healy D (2002). Arrhythmias and sudden death in patients taking antipsychotic drugs. *British Medical Journal* 325.
113. Healy D (2002). Mandel Cohen and the Origins of the Diagnostic and Statistical Manual, Third Edition: DSM-III. *History of Psychiatry* 13, 209-230.
114. Foster J, Finlayson S, Bentall R, Day J, Randall F, Wood P, Reid D, Rogers A, Healy D (2003). The perceived expressed emotion in staff scale. *Journal of Psychiatric and Mental Health Nursing* 10, 109-117.
115. Harris M, Chandran S, Chakroborty N, Healy D (2003). Mood stabilizers: the archaeology of the concept. *Bipolar Disorders* 5, 446-452, Commentary by Paul Grof.
116. Healy D, Thase M (2003). Is academic psychiatry for sale? *Brit J Psychiatry* 182, 1-3.
117. Healy D (2003). Lines of Evidence on SSRIs and Risk of Suicide. *Psychotherapy and Psychosomatics* 72, 71-79.
118. Healy D, Cattell D (2003). The Interface between authorship, industry and science in the domain of therapeutics. *British J of Psychiatry* 182, 22-27.
119. Healy D, Whitaker CJ. (2003) Antidepressants and suicide; Risk-Benefit Conundrums. *J Psychiatry & Neuroscience* 28 (5) 331-339, with response by Y Lapierre 340-349.
120. Healy D (2003). In the grip of the python: conflicts at the university-industry interface. *Science and Engineering Ethics, Special Issue Ethical Issues in Research Relationships at the University Industry Interface*. 9, 59-72.
121. Healy D (2003). Psychopharmacology 102. What they neglected to mention in psychopharmacology 101. *The Clinical Psychologist* 56, 10-27. Commentaries by D Antonuccio & W Danton, I Kirsch, R Levant & M Sammons, M Mavissakalian, & M Thase.
122. Healy D (2004). Shaping the Intimate. Influences on the Experience of Everyday Nerves. *Social Studies of Science* 34, 219-245.
123. Healy D (2004). Conflicting Interests: The evolution of an issue. *Monash Review of Bioethics* 23, 8-18.
124. Healy D (2004). Perspective. Manufacturing Consensus. *Hasting Center Reports* July-August, 53.
125. Healy D (2004). Psychopharmacologie et Histoire: Un Manifeste. *Psychiatrie, Sciences Humaines et Neurosciences* 2, 3-7.

126. Healy D, Harris M, Cattell D, Michael P, Chalasanni P, Hirst D (2005). Service Utilisation in 1896 and 1996: Morbidity and Mortality data from North Wales. *History of Psychiatry* 16, 27-41
127. Chalassani P, Healy D, Morriss R (2005). Presentation and frequency of catatonia in new admissions to two acute psychiatric admission units in India and Wales. *Psychological Medicine* 35, 1667-1675.
128. Harris M, Chandran S, Chakroborty N, Healy D (2005). Service Utilization in Bipolar Disorder, 1890 and 1990 compared. *History of Psychiatry* 16, 423-434.
129. Fergusson D, Doucette S, Cranley-Glass K, Shapiro S, Healy D, Hebert P, Hutton B (2005). The association between suicide attempts and SSRIs: A systematic review of 677 randomized controlled trials representing 85,470 participants. *British Medical Journal* 330, 396-399.
130. Healy D, Aldred G (2005). Antidepressant drug use and the risk of suicide. *International Review of Psychiatry* 17, 163-172.
131. Day JC, Bentall RP, Roberts D, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C (2005). Attitudes towards antipsychotic medication. The impact of clinical variables and relationships with health professionals. *Arch Gen Psychiatry* 62, 717-724.
132. Healy D (2005). Contra Pfizer. *Ethical Human Psychology & Psychiatry* 7, 181-195.
133. Healy D, Herxheimer A, Menkes D (2006). Antidepressants and violence: Problems at the interface of medicine and law. *PLoS Medicine* 3, DOI: 10.1371/journal.pmed.0030372
134. Healy D, Herxheimer A, Menkes D (2007). Antidepressants and violence: Problems at the interface of medicine and law. *Int J Risk & Safety Medicine* 19, 17-33.
135. Healy D (2006). Manufacturing Consensus. *Culture, Medicine and Psychiatry* 30, 135-156. DOI 10.1007/s11013-006-9013-3
136. Healy D (2006). The Antidepressant Tale: Figures Signifying Nothing? *Advances in Psychiatric Treatment* 12, 320-328.
137. Healy D (2006). Neuroleptics and mortality: a 50-year cycle. *British Journal of Psychiatry* 188, 128.
138. Healy D, Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards G, Roberts AP (2006). Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. *British Journal of Psychiatry* 188, 223-228. Commentary by T Turner, 229-230.
139. Healy D (2006). Did regulators fail over selective serotonin reuptake inhibitors. *BMJ* 333, 92-95.

140. Healy D (2006). The Latest Mania. Selling Bipolar Disorder. PloS Medicine. <http://dx.doi.org/10.1371/journal.pmed.0030185>
141. Tschinkel S, Harris M, Le Noury J, Healy D (2007). Postpartum Psychosis: Two Cohorts Compared, 1875-1924 & 1994 – 2005. *Psychological Medicine* 37, 529-536. doi:10.1017/S0033291706009202.
142. Farquhar F, Le Noury J, Tschinkel S, Harris M, Kurien R, Healy D (2007). The incidence and prevalence of manic-melancholic syndromes in North West Wales: 1875-2005. *Acta Psychiatrica Scandinavica* 115, (suppl 433), 37-43.
143. Healy D (2007). The New Engineers of Human Souls and Academia. *Epidemiologia e Psichiatria Sociale* 16. 205-211.
144. Healy D, Le Noury J (2007). Paediatric Bipolar Disorder. An object of study in the creation of an illness. *Int J Risk & Safety in Medicine* 19, 209-221.
145. Healy D (2007). The New Anecdotes. *Ethical Human Psychology & Psychiatry* 9, 131-137.
146. Healy D, Savage M, Tranter R, Austin R, Ijaz Q, Hughes JA, Oberholzer D, Gutting P, Roberts AP (2007). Guidelines, Tramlines, and Faultlines. *Ethical Human Psychology and Psychiatry* 9, 238-244.
147. Reseland S, Le Noury J, Aldred G, Healy D (2008). National suicide rates 1961-2003: further analysis of Nordic data for suicide, autopsies and ill-defined death rates. *Psychotherapy and Psychosomatics* 77, 78-82
148. Healy D (2008). Our Censored Journals. *Mens Sana Monographs* 6, 244-256,
149. Healy D (2008). Irrational Healers? *Psychotherapy and Psychosomatics* 77, 198-200. Doi: 10.1159/000126070
150. Healy D, Harris M, Farquhar F, Tschinkel S, LeNoury J (2008). Historical overview: Kraepelin's impact on psychiatry. *Eur Arch Psychiatry Clin Neurosci* 258, suppl 2, 18-24.
151. Le Noury J, Khan A, Harris M, Wong W, Williams D, Tranter R, Healy D (2008). The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts 1875-1924 and 1994-2006 compared. *BMC Psychiatry* 8: 67. doi:10.1186/1471-244X-8-67.
152. Healy D (2009). Trussed in Evidence: Ambiguities at the interface of clinical practice and clinical evidence. *Transcultural Psychiatry* 46, 16-37. 10.1177/1363461509102285.
153. Healy D, Brent D (2009). Are Selective Serotonin Reuptake Inhibitors a risk factor for adolescent suicides? *Canadian Journal of Psychiatry* 54, 69-71.
154. Healy D (2009). Perplexity is our product. *Canadian J Psychiatry* 54, 76.

155. Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson I (2009). The effect of serotonergic and noradrenergic antidepressants on emotional processing in clinically depressed patients. *Journal of Affective Disorders* 118, 87-93.
156. Healy D, Morgan R, Chinnaswamy S (2009). Transient global amnesia associated with statin intake. *BMJ Case Reports* doi:10.1136/bcr.06.2008.0033.
157. Healy D, Mangin D (2009). The Once and Future Psychiatry. *Academic Medicine* 84, 418-420.
158. Linden S, Harris M, Whitaker C, Healy D (2010). Religion and psychosis. The effects of the Welsh Religious Revival 1904-1905. *Psychological Medicine* 40, 1317-1324. doi:10.1017/S0033291709991917
159. Davies P, Healy D, Davies E, Green P (2009). Selenium and stereotypies in a mental health setting. *BMJ Case Reports* 2009, doi: 10.1136/bcr.07.2009.2053
160. Healy D, Mangin D, Mintzes B (2010). The ethics of randomized placebo controlled trials of antidepressants with pregnant women. *Internat J of Risk and Safety in Medicine* 22, 7-16 DOI 10.3233/JRS-2010-0487
161. Johnston S, Boehm S, Healy D, Goebel R, Linden DE (2010). Neurofeedback: a promising tool for the self-regulation of emotion networks. *Neuroimage* 49, 1066-1072.
162. Linden SC, Jackson MC, Subramanian L, Wolf C, Green P, Healy D, Linden DEJ (2010). Emotion-cognition interactions in schizophrenia: Implicit and explicit effects of facial expression *Neuropsychologia*
163. Le Noury J, Tatineni R, Healy D (2010). Perceptions of adult ADHD. *International J of Risk and Safety in Medicine* 22, 55-58. DOI 10.3233/JRS-2010-0492
164. Parker G, Fink M, Shorter E, Taylor MA, Akiskal H, Berrios G, Bolwig T, Brown WA, Carroll B, Healy D, Klein DF., Koukopoulos A, Michels R, Paris J, Rubin RT, Spitzer R, Swartz C (2010) Whither Melancholia? The Case for its Classification as a Distinct Mood Disorder. *American J Psychiatry* 167, 745-746.
165. Johnston S, Linden DE, Healy D, Goebel R, Habes I, Boehm S (2010). Upregulation of emotion areas through neurofeedback with a focus on positive mood. *Cognitive, Affective and Behavioral Neuroscience* DOI.1013758/s13415-010-0010-1.
166. Linden DEJ, Habes I, Johnston SJ, Linden S, Tatineni R, Subramanian L, Sorger B, Healy D, Goebel R (2012). Real-time self-regulation of emotion networks in patients with depression. *PLoS One* 7 (6) e38115. Doi: 10.1371/journal.pone.0038115
167. Harris M, Farquhar F, Healy D, LeNoury J, Baker D, Whitaker CJ, Linden S, Green P, Roberts AP (2011). The incidence and prevalence of admissions for Melancholia in two cohorts 1875-1924 & 1995-2005. *J of Affective Disorders* 134, 45-51. doi:[10.1016/j.jad.2011.06.015](https://doi.org/10.1016/j.jad.2011.06.015)
168. Francis AN, Fink M, Appiani F, Bertelsen A, Bolwig T, Braeunig P, Caroff SN, Carroll BT, Cavanna A, Cohen D, Cottencin O, Cuesta NJ, Daniels J, Dhossche D,

- Fricchione G, Gazdag G, Neera G, Healy D, Klein D, Krueger S, Lee J, Mann S, Mazurek M, McCall V, McDaniel W, Northoff G, Peralta V, Petrides G, Rosebush P, Rummans T, Shorter E, Suzuki K, Thomas P, Vaiva G, Wachtel L. Catatonia in DSM 5, Journal of ECT, 26, 246-247.
169. Rosenlicht N, Tsai AC, Parry PI, Spielmans G, Jureidini J, Healy D (2011). Aripiprazole in the maintenance treatment of bipolar disorder: A critical review of the evidence and its dissemination into the scientific literature. PLoS Medicine, 8, e10000434.
170. Linden SC, Jackson MC, Subramanian L, Healy D, Linden D (2011). Sad benefit in face working memory: an emotional bias in melancholic depression. J Affective Disorders 135, 252-257. doi:[10.1016/j.jad.2011.08.002](https://doi.org/10.1016/j.jad.2011.08.002)
171. Healy D, Le Noury J, Linden SC, Harris M, Whitaker CJ, Linden D, Baker D, Roberts AP (2012). The Rise and Fall in the Incidence of Admissions for Schizophrenia: 1875-1924 & 1994-2010. BMJ Open 2:e000447. doi:10.1136/bmjopen-2011-000447.
172. Wolf C, Linden S, Jackson MC, Healy D, Baird A, Linden D, Thome J (2011). Brain activity supporting working memory accuracy in patients with paranoid schizophrenia: a functional magnetic resonance imaging study. Neuropsychobiology 64, 93-101.
173. Body D, Edwards IR, Hartigan Go K, Herxheimer A, Labadie J, Healy D (2011). Is there a need for Forensic Pharmacovigilance as a specialty. International Journal of Risk & Safety in Medicine 23, 31-42.
174. Healy D (2011). Science, rhetoric and the causality of adverse events. Int J Risk & Safety in Medicine 24, 149-162, DOI 10.3233/JRS-2011-534
175. Healy D, Le Noury J, Whitaker C, Harris M, Linden S, Linden D, Roberts AP (2012). Mortality for Schizophrenia & Related Psychoses in two cohorts: 1875-1924 & 1994-2010. BMJ Open. 2:e001810.doi:10.1136/bmjopen-2012-001810
176. Healy D, Le Noury J, Whitaker C, Harris M, Linden S, Linden D, Roberts AP. Service Utilization and other outcomes for Schizophrenia & Related Psychoses in two cohorts: 1875-1924 & 1994-2010. (In prep).
177. Herxheimer A, Healy D, Menkes D (2012). Case Histories as evidence. International J Risk & Safety in Medicine 24, 23-29. DOI 10.3233/JRS-2012-0549
178. Persaud N, Healy D (2012). Epidemiology in forensic pharmacovigilance. International J Risk & Safety in Medicine 24, 31-35. DOI 10.3233/JRS-2012-0550
179. Healy D (2012). Medical Partizans? Why doctors need conflicting interests. Australian & New Zealand Journal of Psychiatry 46(8) 704–707, DOI: 10.1177/0004867412454197
180. Healy D (2012). Controlled trials and adverse events: lessons from the history of antidepressants and suicide. Radical Statistics

181. Habes I, Krall SC, Johnson SJ, Yuen KSL, Healy D, Goebel R, Sorger B, Linden DEJ (2013). Pattern classification of valence in depression. *Neuroimage: Clinical* 2, 675-683.
182. Healy D, Mangin D, Antonuccio D (2013). Data Based Medicine & Clinical Judgement. *International J of Risk & Safety in Medicine* 25, 111-121. With commentary by Edwards R Data and Evidence, There is a Difference, *IJRSM* 25, 123-129.
183. Harris M, Farquhar F, Healy D, Le Noury J, Linden S, Hughes A, Roberts AP (2013). Aspects of melancholia: Two Cohorts 1875-1924 & 1995-2005 compared. *History of Psychiatry* 24, 3-14.
184. Healy D (2013). Catatonia from Kahlbaum to DSM 5. *Australian and NZ Journal of Psychiatry* DOI: 10.1177/0004867413486584
185. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T (2013). Restoring invisible and abandoned trials: a call for people to publish the findings. *BMJ* 346: f2865 doi: 10.1136/bmj.f2865
186. Healy D (2012). Brand "fascism" and academic stalking. *Journal of Biological Physics and Chemistry*.
187. Atigari O, Kelly AM, Jabeen Q, Healy D (2013). New onset alcohol dependence linked to treatment with SSRIs. *Int J of Risk & Safety in Medicine* 25, 105-109.
188. Atigari O, Healy D (2013). Proconvulsant effects. A neglected dimension of psychotropic activity. *Australian and New Zealand Journal of Psychiatry* 47, 998-1001.
189. Healy D (2013). Melancholia: Past and Present. *Can J Psychiatry* 58, 190-194.
190. Atigari O, Healy D (2013). Sustained antidepressant response to ketamine. *BMJ Case Reports*, doi 10.1136/bcr-2013-200370.
191. Lefever-Watson G, Arcona, A, Antonuccio D, Healy D (2013). Shooting the messenger: the case of ADHD. *J Contemporary Psychotherapy*. 10.1007/s10879-013-9244-x
192. Basa F, Harris M, Syed MA, LeNoury J, Healy D (2014). Mental health admissions in paediatric populations in North Wales: Two cohorts; 1875-1925 and 1994-2008. *BMJ Open*. 4:e004331. doi:10.1136/bmjopen-2013-004331
193. Atigari O, Healy D (2013). Etanercept and schizophrenia like psychosis. *BMJ Case Reports* doi:10.1136/bcr-2013-200464
194. Atigari, Hogan C, Healy D (2013). Doxycycline and suicidality. *BMJ Case Reports* doi:10.1136/bcr-2013-200723
195. Healy D, Bechtold K, Tolias P (2014). Antidepressant-Induced Suicidality: How Translational Epidemiology incorporating Pharmacogenetics into Controlled Trials can Improve Clinical Care. *Personalized Medicine* 11, 79-88.



196. Healy D, Howe G, Mangin D (2014). Sudden Cardiac Death and the Reverse Dodo Verdict. *International J Risk & Safety in Medicine* 26, 71-79.
197. Brookwell L, Hogan C, Mangin D, Healy D (2014). One hundred cases of alcoholism triggered by serotonin reuptake inhibitor intake. *Int J Risk & Safety in Medicine* 26, 99 – 107.
198. Hogan C, Le Noury J, Healy D, Mangin D (2014). One hundred and twenty cases of enduring sexual dysfunction following treatment. *International J Risk and Safety in Medicine* 26, 109-116.
199. Healy D, Mangin D, Applbaum K (2014). The Shipwreck of the Singular. *Social Studies of Science* 44, 518-523.
200. Healy D (2014). Psychiatric Disease in History. *History of Psychiatry* 25, 450-458.
201. Atigari O, Harris M, Hogan C, LeNoury J, Healy D (2016). Incidence, prevalence and outcomes of admissions for Bipolar Disorder: Two cohorts compared 1875-1924 and 1904-2007. *History of Psychiatry* 27, 1-10, DOI: 10.1177/0957154X15624601
202. Hogberg G, Antonuccio D, Healy D (2015). Suicidal Risk from TADS Study Was Higher than it First Appeared. *Int J Risk & Safety in Medicine* 27, 85-91. DOI 10.3233/JRS-150645
203. Healy D. Interview with Steven Katz & Kevin Peters. *Dementia* 2015; 14; 361-369.
204. Naudet F, Falissard B, Healy D, Boussageon R (2015). Has evidence-based medicine left quackery behind? *Internal and Emergency Medicine* 10, 631-634.
205. Healy D (2015). Serotonin and Depression. The Marketing of a Myth. *The BMJ* 350: h1771 doi: 10.1136/bmj.h1771
206. Le Noury J, Nardo J, Healy D, Jureidini J, Raven M, Aba-Jaoude E, Tufanaru C (2015). Restoring Study 329: A randomised, controlled trial of the efficacy and harms of paroxetine and imipramine in the treatment of adolescent major depression *BMJ* 2015; 351: h4320 | doi: 10.1136/bmj.h4320
207. Healy D, Le Noury J, Mangin D (2016). Links between Serotonin Reuptake Inhibition Pregnancy & Neurodevelopmental Delay Spectrum Disorders: A Review of Epidemiological and Physiological Evidence. *Int J Risk & Safety in Medicine* 28, 125–141 DOI 10.3233/JRS-160726
208. Le Noury J, Nardo J, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E (2016). Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. *Int J Risk and Safety in Medicine* 28, 143–161 DOI 10.3233/JRS-160728.

209. Healy D, Le Noury J, Jureidini J (2018). Los antidepresivos en pediatría: ¿el mayor fracaso de la asistencia sanitaria? *Revista de la Asociación Española de Neuropsiquiatría* 37, 133 / Healy
210. Healy D, Le Noury J, Jureidini J (2019). Paediatric antidepressants; benefits and risks. *International J or Risk & Safety in Medicine* 30, 1-7.
211. Healy D, Le Noury J, Mangin D (2018). Enduring sexual dysfunction after treatment with antidepressants, 5 $\alpha$ -reductase inhibitors and isotretinoin: 300 cases. *Int J Risk and Safety in Medicine*, 29, 3, 125-134. DOI 10.3233/JRS-180744
212. Healy D, Le Noury J, Mangin D et al. (2018). Citizen petition: Sexual side effects of SSRIs and SNRIs. *Int J Risk and Safety in Medicine*, 29, 135-147. DOI 10.3233/JRS-180745
213. Berard A, Levin M, Sadler T, Healy D (2018) Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Major Malformations: The Importance of Serotonin for Embryonic Development and the Effect of Serotonin Inhibition on the Occurrence of Malformations. *Bioelectricity* 2018, 1, 18-29. [doi.org/10.1089/bioe.2018.0003](https://doi.org/10.1089/bioe.2018.0003)
214. Healy D. The crisis in Cochrane: Evidence Debased Medicine. *Indian J Med Ethics*. 2019; 4: 52-4.
215. Healy D. Antidepressants for Minors: Benefits, Risks and Peter Gøtzsche. *Bipolar Disorder* 2019, 21, 797-798.
216. Healy D, Le Noury J, Mangin D. Post-SSRI sexual dysfunction: Patient experiences of engagement with healthcare professionals. *International Journal of Risk & Safety in Medicine* 2019, 31, 1–7, DOI 10.3233/JRS-191005
217. Healy D (2019). Post-SSRI sexual dysfunction & other enduring sexual dysfunctions. *Epidemiology and Psychiatric Sciences* 29: 1–2.
218. Healy D, LaPalme J, Levin M (2019). Post-Selective Serotonin Reuptake Inhibitor Sexual Dysfunction: A Bioelectric Mechanism? *Bioelectricity* <https://doi.org/10.1089/bioe.2019.0010>
219. Healy D, Mangin D (2019). Clinical judgments, not algorithms, are key to patient safety. *BMJ* 367: l5777
220. Healy D (2020). Antidepressants and sexual dysfunction, a history. *Journal of the Royal Society of Medicine* 113, 133-135.
221. Bijl D, Healy D (2020) Inadequate evaluation of potential side effects of sildenafil in preterm stopped Dutch trial. *Int J Risk and Safety in Medicine* 31, 145-148.
222. Healy D (2020). Medical Nihilism by Jacob Stegenga; Is operationalism the answer to nihilism? *Studies in the History and Philosophy of Biology and Biomedical Sciences* 81, 101272.

223. LaPorte, JR, Healy D. In the midst of the SARS-CoV-2 pandemic, caution is needed with commonly used drugs that increase the risk of pneumonia. At a time when the BMJ and Lancet were taking any articles that mentioned Covid, even from Surgisphere, this article was turned down by both journals. It was published on RxISK.org and 3 studies have now supported the central thesis of the piece.
224. Johnson RM, Doshi P, Healy D (2020). Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available? BMJ 2020;370:m3260
225. Healy D (2022). Reducing medication burden has become a privilege of wealth in western settings. Indian Journal of Medical Ethics 30, 226-229.
226. Healy D (2022). Whistleblowing without names is hearsay. Indian Journal of Medical Ethics 30, 194-196.
227. Healy D, Lochhead J, Mangin D (2022). Development and persistence of patient reported visual problems associated with serotonin reuptake inhibiting antidepressants. Int J Risk & Safety in Medicine 2021, 33, 37-47.
228. Healy D, Bahrack A, Bak M, Barbato A, Calabrò RS, Chubak BM, Cosci F, Csoka AB, D'Avanzo B, Diviccaro S, Giatti S, Goldstein I, Graf H, Hellstrom WJ, Irwig MS, Jannini EA, Janssen PK, Khera M, Kumar MT, Le Noury J, Lew-Starowicz M, Linden DE, Lüning C, Mangin D, Melcangi RC, Shaban Rodríguez OW, Panicker JN, Patacchini A., Pearlman AM, Pukall CF, Raj S, Reisman Y, Rubin RS, Schreiber R, Shipko S, Vašečková B, Waraich A. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk and Safety in Medicine 2022, 1-7
229. Goetzsche P, Healy D. Restoring the two pivotal fluoxetine trials in children and adolescents with depression. Int J Risk ^ Safety in Med 2022, 33, 385-408.
230. Healy D. Toward Zombie Psychiatry. Indian J Med Ethics, 2022, 7.
231. Healy D, Roux A, Dressen B. The coverage of medical injuries in company trial informed consent forms. Int J Risk & Safety in Med 2023.
232. Healy D. Diagnosis, Verdict and Causality. Ethical Human Psychology and Psychiatry 2023
233. Healy D.

Other articles are in preparation on:

Acute and Transient Psychosis: Historical and Contemporary Trajectories,  
Acute and Transient Mental Illness: Lessons from Historical Records.

## BOOK CHAPTERS

1. Healy D, Carney PA & Leonard B E (1985). Circadian abnormalities in platelet 5HT reuptake in depression. In *Circadian Rhythms in the Central Nervous System*, ed Redfern PH et al. Macmillan Press, Basingstoke, 249-252 (CPA).
2. Healy D (1988). Olfactory Bulbectomy and Depression. In *Animal Models of Psychiatric Disorders* ed Soubrie P et al, 1, 110-114, Karger, Basel (PA).
3. Healy D and Paykel ES (1989). The Neurochemistry of Depression. In *Modern Perspectives in the Psychiatry of the Affective Disorders*, ed Howells, J G, Brunner/Mazel, New York. pps 20-50 (PA).
4. Healy, D (1990). Rhythm and Blues. In *Antidepressants: Thirty Years On*, ed Leonard B E, Spencer P CNS Neuroscience Publishers, London, 169-175 (PA).
5. Healy D (1991). The Role of Irish Members in the Medico- Psychological Association. Plus ca Change. In *150 Years of British Psychiatry* ed Berrios G E, Freeman H L, Gaskell, pp 314- 320 (PA).
6. Healy D, Paykel E S (1992). Neurochemical Correlates of Affective Processes. In Asbury A K, McKhann G M & McDonald W I, *Diseases of the Nervous System*, Harcourt Brace and Jovanovich, PP 815-830 (PA).
7. Lynch T & Healy D (1993). In Conversation with Tom Lynch. In *Talking About Psychiatry*, ed Wilkinson G, Gaskell Press, London (CPA).
8. Healy D (1993). Dysphoria. In *Symptoms of Depression*. ed Costello G Wiley J., pp 24-45 (PA).
9. Healy D (1993). Neuropsychology, pharmacopsychology and schizophrenia. in *Schizophrenia: Aspects and Controversies* ed Bogte H, Verhoeven W M A, Foundation of Neuropsychiatry, Maastricht, pp 30 – 40 (PA).
10. Healy D (1995). Involving users in mental health services in the era of the word-processor and the database. in *Community Care: Evaluation of the Provision of Mental Health Services* ed Crosby C, Barry M, Avebury Press, Aldershot, 209-231.
11. Healy D, Watson F (1995). Human volunteers in human psychopharmacology: Problems and opportunities. in Hindmarch I, Stonier P eds. *Human Psychopharmacology: Materials and Methods*, Vol 5, J Wiley, Chichester, pp 63-87 (CPA).
12. Healy D (1996). Psychopharmacology in the new medical state. in Eds Healy D, Doogan D *Psychotropic Drug Development: Social Economic and Political Issues*, Chapman and Hall, London, pp 15-39 (PA).
13. Healy D, Doogan D (1996). Psychopharmacology in a time of transition. in Eds Healy D, Doogan D, *Psychotropic Drug Development: Social Economic and Political Issues*, Chapman and Hall, London (PA).

14. Healy D (1996). Irish Psychiatry in the Twentieth Century: Notes Towards a History. in 150 Years of British Psychiatry, Vol 2 ed Freeman H & Berrios GE, Athlone Press, London, 268-291 (PA).
15. Healy D (1996). The history of British Psychopharmacology. in 150 Years of British Psychiatry, Vol 2 ed Freeman H, Berrios GE, Athlone Press, London, p 61-88 (PA).
16. Bentall R, Day J, Rogers A, Healy D, Stevenson R C (1996). Side effects of Neuroleptic Medication: Assessment and impact on outcome of psychotic disorders. in Hdbk of Mental Health Economics and Health Policy, Vol 1 Schizophrenia Ed Moscarelli M, Rupp A & Sartorius N, J Wiley & Sons Chichester, p 133-148 (CPA).
17. Healy D (1998). Drugs & Industry. In Ban TA, Healy D, Shorter E (eds). The Rise of Psychopharmacology & The Story of the CINP, Animula, Budapest. p 51-55 (PA).
18. Healy D (1999). The Origin of the Antidepressants. In Freeman HF (Ed), A Century of Psychiatry, Volume 1, Mosby London, pp 169-173 (PA).
19. Healy D (1999). Arvid Carlsson. In Freeman HF (Ed), A Century of Psychiatry, Volume 1, Mosby, London pp 180-181 (PA).
20. Healy D (1999). Psychopharmacology 2000. In Freeman HF (ed), A Century of Psychiatry, Volume 2, Mosby London, 352-358 (PA).
21. Healy D, McMonagle T (1998). The Prophylaxis of Affective Episodes, O'Mahoney G, Lucey JV, Understanding Psychiatric Treatment, J Wiley & Sons, pp 115-131.
22. Healy D (2000). The Antidepressant Story. In Nowotny H, Folkers G, Sternwarten-Buch Vol 2, Haffmans Sachbuch Verlag Zurich, pp (PA)
23. Healy D (2001). The Antidepressant Drama. In Weissman M ed. Treatment of Depression. Bridging the 21<sup>st</sup> Century. Proc Am Psychopathological Assoc Meeting March 1999, APA Press, Washington D.C pp 7-34 (PA).
24. Healy D (2001). The SSRI Suicides. In Newnes C, Holmes G, Dunn C (ed), This is Madness Too. PCSS Books, Ross-on-Wye, pp 59-69.
25. Healy D (2001). Fifty Years of Depression. In Dawson A, Tylee A (eds.) Depression: social and economic timebomb. BMJ Books, London, pp.45-48.
26. Randall F, Wood P, Day J, Bentall R, Rogers A, Healy D (2001). Enhancing appropriate adherence with neuroleptic medication: Two contrasting approaches. In Morrison AP (ed). A Casebook of Cognitive Therapy for Psychosis. Brunner-Routledge, London, 281-298.
27. Healy D (2002). Antipsychotics: The Historical Record. In Green B (ed). Focus on Antipsychotics, Petroc Press, Berkshire, pp 4-9.
28. Healy D (2002). Depression. In The New Dictionary of Pastoral Studies, ed Carr W, et al, SPCK Press, London, pp 92-94.

29. Healy D, Kuhn R, Simon P, Broadhurst A, Shorter E, Battegay R, Voelkel A, Cahn CH (2002). The Imipramine Dossier. In Ban T, Healy D, Shorter E (ed), *From Neuropsychopharmacology to Psychopharmacology in the 1980s*. Animula, Budapest, pp 281-352.
30. Healy D (2004). Psychopharmacology at the Interface between the market and the New Biology. In Rose SPR, Bateson P, *Perils and Progress*, Cambridge University Press, Cambridge, pp 232-248.
31. Healy D (2005). Psychopharmacological histories through the looking glass of advancing years. In Curran S, Bullock R (eds), *Psychopharmacology for the Aged, Practical Aspects*, Ratcliffe Medical Press.
32. Healy D (2004). You Have No Right to Present this Research. In Bruneau W, Turk JL (ed.) *Disciplining Dissent*. Lorimer Toronto, pp 53-73.
33. Healy D (2004). The Foundation of the British Association of Psychopharmacology. In Ban T, Healy D, Shorter E, *Psychopharmacology Retrospective*, Animula, Budapest.
34. Healy D (2004). Good Science or Good Business. In Chambers T, Elliott C (eds). *Prozac as a Way of Life*. University of North Carolina Press, Chapel Hill S Carolina, 72-79.
35. Healy D (2005). The Medico-legal interface between Law and Science: From Thalidomide to Prozac. In Tomossy G, et al.
36. Healy D (2004). Drug Regulation and the introduction of psychotropic drugs in the United Kingdom. In Ban T, Healy D, Shorter E. *Reflections on Twentieth Century Psychopharmacology*. Animula, Budapest, pp 94-97.
37. Healy D (2004). Michael Shepherd, Founder and Vice-President (1957-1958). In Ban T, Healy D, Shorter E. *Reflections on Twentieth Century Psychopharmacology*. Animula, Budapest, pp 577-578.
38. Healy D (2004). The History of the British Association for Psychopharmacology. In Ban T, Healy D, Shorter E. *Reflections on Twentieth Century Psychopharmacology*. Animula, Budapest, pp 628-630.
39. Healy D (2005). Shaping Discontent. The Roles of Science and Marketing. In Pietekainen P (ed). *Modernity and Its Discontents: Sceptical Essays on the Psycho-medical Management of Malaise*. Stockholm: Ax:son Johnson Foundation, pp 33-48.
40. Healy D (2004). A l'heure des antidépresseurs. In Chapelle G (ed). *Le Moi. Du Normal au pathologique*. Éditions Sciences Humaines, Auxerre, 319-325.
41. Healy D (2006). The New Medical Oikumene. In Petryna A, Lakoff A, Kleinman A (ed) *Global Pharmaceuticals. Ethics, Markets, Practices*. Duke University Press, Durham, pp 61-84

42. Healy D (2006). Psychopharmacology and the Quantities of the Brain. In Ban T, Ucha Udabe R, (Ed) The Neurotransmitter Era in Neuropsychopharmacology in a Historical Perspective. Editorial Polemos, Buenos Aires, pp 247-254.
43. Healy D (2007). Folie to Folly, The Modern Mania for Bipolar Disorders and Mood Stabilizers. In Tone A, Watkins ES (ed). Medicating Modern America. Prescription Drugs in History. New York University Press pp 42-62.
44. Healy D, Le Noury J (2007). Bipolar Syndrome by Proxy. The Strange Case of Pediatric Bipolar Disorder. In Olfman S (ed). Bipolar Disorder in Children: Cutting Edge Controversies. Praeger Press, 12-27
45. Healy D (2008). The Intersection of Psychiatry and Psychopharmacology in the Second Half of the Twentieth Century. In Wallace ER, Gach J (eds) History of Psychiatry and Medical Psychology. New York, Springer, pp 419-437.
46. Healy D (2008). Birth, Ritalin, Prozac, Viagra, Death. In Bennett , Carney T, Karpin I (eds). The Brave New World of Health. Federation Press, Sydney p 112-127.
47. Healy D, Moore N (2008). Treatment of Psychiatric Disorders. In Boxtel CJ van, Santoso B, Edwards IR (eds). Drug Benefits and Risks: International Textbook of Clinical Pharmacology. IOS Press, p 675-684.
48. Healy D (2008). Academic Stalking and Brand Fascism. In Turk J, Thompson J Universities at Risk: How Politics, Special Interests and Corporatization Threaten Academic Integrity. Lorimer Press, Toronto p 108-137.
49. Healy D (2009). Notes Towards A Future History of Treatments for Cognitive Failure. In Treating Dementia. Do We Have a Pill for That? Ed. Jess Ballenger, Peter Whitehouse, Constantine Lyketsos, Peter Rabins and Jason Karlawish. Johns Hopkins University Press, Baltimore pp 25-41.
50. Healy D (2010). From Mania to Bipolar Disorder, Yatham L, Maj M (eds) Bipolar Disorder: Clinical and Neurobiological Foundations, J Wiley & Sons, New York, pp 1-7.
51. Healy D (2011). Dependence on Drugs. HAI Holland
52. Healy D (2013). Le Meilleur de Marchés. Ed Borch-Jacobsen M. Big Pharma. Une industrie toute-puissante qui joue avec notre santé. Les Arenes Paris, 399-426.
53. Healy D (2014). Challenging the dominance of the pharmaceutical industry in psychiatry. In Higgins A and McDaid S (eds). Mental Health in Ireland. Gill & MacMillan, Dublin, pp 251-269.
54. Healy D, Le Noury J (2014). Pediatric Bipolar Disorder. An Object of Study in the Creation of an Illness. In Holmes D, Jacob JD, Perron A. Power and the Psychiatric Apparatus. Ashgate, Surrey pp 117-133.
55. Healy D (2014). The Cardinals of Psychiatry. In Speed E, Moncrieff J, Rapley M (eds). De-Medicalizing Misery II. Palgrave MacMillan, London pp 174-189.

56. Healy D, Mangin D (2016). Does my Bias look Big in This? In Baylis F, Ballantyne A, Clinical Research Involving Pregnant Women. Springer International Publishing, Switzerland, pp 197-208, DOI 10.1007/978-3-319-26512-4\_11
57. Healy D, Le Noury J, Jureidini. The Greatest Failing in Healthcare.
58. Healy D. The Pharmaceutical Industry and the Standardization of Psychiatric Practice. In Ikkos G, Bouras N (Eds) Mind, State and Society. Social History of Psychiatry and Mental Health in Britain 1960-2010. Cambridge U Press 163-170. (2021).
59. Healy D. The Pharmaceutical Industry and American Health Services. Halliwell M, Jones S (Eds). The Politics of American Health. Edinburgh University Press (2022).



**JOURNAL REVIEWER FOR:**

1. Academic Medicine
2. Acta Psychiatrica Scandinavia
3. Acta Neurological Scandinavia
4. Annals of Internal Medicine
5. Anthropology and Medicine
6. Archives of General Psychiatry
7. Australasian Psychiatry
8. Behavioural Pharmacology
9. British Journal of Psychiatry
10. British Journal of Clinical Pharmacology
11. British Journal of Hospital Medicine
12. British Medical Journal
13. Biological Psychiatry
14. Biomedical Central
15. Bipolar Disorders
16. BMJ Case Reports
17. BMJ Evidence Centre
18. Bulletin of History of Medicine
19. Business History Review
20. Canadian Medical Association Journal
21. Chemical Heritage
22. Chronobiology International
23. Clinical Practice & Epidemiology in Mental Health
24. CNS Drugs
25. Contemporary Psychology
26. Culture, Medicine & Psychiatry
27. Current Medical Research & Opinion
28. Current Anthropology
29. Depression and Anxiety
30. Disease Management & Health Outcomes
31. European Neuropsychopharmacology
32. Evidence Based Mental Health
33. Expert Review of Neurotherapeutics
34. Harvard Review of Psychiatry
35. Hastings Center Report
36. History of Psychiatry
37. History of Psychology
38. History of the Human Sciences
39. Human Psychopharmacology
40. International Journal of Geriatric Psychiatric
41. International Journal of Clinical Medicine
42. International Journal of Clinical Psychopharmacology
43. International Journal of Law and Psychiatry
44. International Journal of Neuropsychopharmacology
45. International Journal of Psychiatry in Clinical Practice
46. Internet Journal of Mental Health
47. Irish Journal of Medical Science
48. Irish Journal of Psychological Medicine

49. Journal of Abnormal Psychology
50. Journal of Affective Disorders
51. Journal of Attention Disorders
52. Journal of Child Psychology and Psychiatry
53. Journal of Clinical Psychiatry
54. Journal of the History of the Behavioral Sciences
55. Journal of Mental Deficiency Research
56. Journal of Nervous & Mental Disease
57. Journal of Mental Health
58. Journal of Personality & Social Psychology
59. Journal of Psychiatry & Neuroscience
60. Journal of Royal Society of Medicine
61. Journal of Sex and Marital Therapy
62. Journal of Social and Clinical Psychology
63. Journal of Psychopharmacology
64. Lancet
65. Life Sciences
66. MD Adviser
67. Medical History
68. Medical Hypotheses
69. Mens Sana Monographs
70. Monash Bioethics Review
71. Nature Medicine
72. Nature Neuroscience
73. Neuropsychiatric Disease & Treatment
74. Neuropsychopharmacology
75. Perspectives in Biology & Medicine
76. Pharmacogenomics.
77. Pharmacology, Biochemistry & Behaviour
78. Philosophy, Psychology & Psychiatry
79. Philosophy, Ethics and Humanities in Medicine
80. PLoS Medicine
81. PLoS One
82. Primary Care Psychiatry
83. Progress in Neuropharmacology & Biological Psychiatry
84. Psychiatric Bulletin
85. Psychiatry Research
86. Psychological Medicine
87. Psychology & Psychotherapy
88. Psychopharmacology
89. Psychosis
90. Psychotherapy & Psychosomatics
91. Public Library of Science: Medicine
92. Public Library of Science: One
93. Quarterly Journal of Mental Health
94. R&D Management
95. Science & Engineering Ethics
96. Science Studies
97. Social History of Medicine
98. Social Science and Medicine
99. Social Studies of Science

- 100. Studies in History and Philosophy of Biological and Biomedical Sciences
- 101. The Hedgehog Review
- 102. The Psychologist
- 103. Transcultural Psychiatry
- 104. World Psychiatry

**ASSESSOR FOR:**

- 1/ Agence d'évaluation des technologies et des modes d'intervention en santé de Québec.
- 2/ American Psychological Association:  
Guidelines on the Treatment of Children & Adolescents.
- 3/ Royal Australian College of Physicians:  
Revision of guidelines for ethical relationships between physicians and industry
- 4/ Royal College of Psychiatrists:  
Revision of guidelines on relationships between physicians and the pharmaceutical industry

Drugs and Therapeutics Bulletin  
Fullbright Fellowship Program  
Health Which?  
Medicine's Resource Centre Bulletin  
Welsh Health Gains Initiative

## UNIVERSITY PRESS & PUBLISHER REVIEWS

1. Anansi Press
2. Basic Books
3. Bloomsbury USA
4. Bodley Head
5. Cambridge University Press
6. Chapman & Hall
7. Columbia University Press
8. Duke University Press
9. Encyclopedia of Social Measurement – Elsevier
10. Harvard University Press
11. Hodder & Arnold
12. Johns Hopkins University Press
13. Martin Dunitz Press.
14. New York University Press
15. Oxford University Press
16. Pantheon Books
17. Praeger Publishers
18. Random House
19. Routledge
20. Simon & Shuster
21. St Martins' Press
22. Times Literary Supplement
23. University of California Press.
24. University of Regina Press
25. University of South Carolina Press
26. Vanderbilt University Press

## EDITORIAL BOARD

|                                     |                              |
|-------------------------------------|------------------------------|
| Human Psychopharmacology            | 1990 – 2000                  |
| Primary Care & Community Psychiatry | 1995 – 2005                  |
| History of Psychiatry               | 2002 – Associate Editor 2012 |
| Medical Hypotheses                  | 2003 – 2010                  |
| Mens Sana Monographs                | 2007 –                       |
| Psychosis                           | 2007 –                       |

## GRANT REVIEWER

1. ESRC
2. Canadian Institutes of Health Research
3. MacArthur Fellowship Reviewer
4. Medical Research Council of Canada
5. Medical & Social Science Research Board
6. Mental Health Foundation
7. National Institute for Health Research
8. National Lotteries Charities Board
9. National Science Foundation
10. Scottish Health Board
11. Social Sciences & Humanities Research Council of Canada
12. Wellcome Trust
13. Welsh NHS Research and Development Board

### **Academic Promotion Review**

1. Renselaar Polytechnic Institute
2. Trent University
3. University of California, Los Angeles

### **GOVERNMENT CONSULTANT**

Medical and HealthCare Devices Regulatory Agency (UK) 2001-2004 on SSRIs

Senator Grassley's Office US re SSRIs

Congressmen Barton and Greenwood US re SSRIs

House of Commons Health Select Cttee on the Influence of the Pharmaceutical Industry.

Comité d'évaluation des pratiques médicales en matière de médicaments (Belgium)

## ABSTRACTS, REVIEWS, CONSENSUS STATEMENTS, LETTERS

1. Healy D, Carney A P, Leonard B E (1984). Abnormalities in the Circadian Regulation of 5HT Uptake into the Platelets of Depressed Persons. *Clinical Neuropsychopharmacol.*
2. Healy D, Carney A P, O'Halloran A (1984). Use of a Microcomputer to rate Depression in a West of Ireland Population. *Clinical Neuropsychopharmacology.*
3. Healy D, Paykel E S, Theodorou A E, Horton R (1988). The effect of treatment with and withdrawal from antidepressants on platelet 3H Imipramine binding in volunteers. *Journal of Psychopharmacology*, 2, 2
4. Healy, D (1988). Antidepressants and Mania. *American J of Psychiatry*, 145, 706-707.
5. Healy D (1988). Rhythm & Blues: the role of the circadian rhythm disturbances in the pathogenesis of the affective disorders. *J Psychopharmacology*, 2, 3 abstract.
6. Healy D (1987). Depression & Mania; Modern Lithium Treatment. *J Psychopharmacology* 1, 274-275.
7. Healy D, Paykel ES, Whitehouse AM, White W, Brown M, Ashby M, Theodorou AE, Horton RW (1989). Plasma noradrenaline, adrenaline and DHPG levels in depression before and after clonidine. *J Psychopharmacology* 3, 4.
8. Healy D (1990). Prescribing rights for psychologists? *The Psychologist* 556-557.
9. Healy D (1991). Biological bases of dementia. *J Psychopharmacology* 5, 437-444.
10. Creaney W, Murray I, Healy D (1992). Antidepressant induced suicidal ideation. *Journal of Psychopharmacology* 6, Abstracts of Annual BAP Meeting, 120.
11. Healy D, Calvert J, White W, Whitehouse AM Paykel E S (1992) Acid Alpha-1 Glycoprotein levels in Depression. *J Psychopharmacol* 6, Abstracts Ann Meeting 1991.
12. Healy D (1991). Altered States of Consciousness: Phenomenology and Pharmacology. *Journal of Psychopharmacology Abstracts of Annual Meeting.*
13. Healy D (1992). Pandora's Box. *Journal of Psychopharmacology* 6, 444-446.
14. Healy D (1991). The Anxiolytic Jungle. Where Next? *Psychol Medicine* 21, 791-812.
15. Healy D (1991). Medical Choices; Medical Chances. *Irish J Psychological Med* 8, 189
16. Healy D, Creaney W (1991). Antidepressant induced suicidal ideation. *British Medical Journal* 303, 1058-1059.
17. Healy D, Waterhouse (1992). Endogenous Rhythms, Reactive Clocks and Non-Specific Drugs. *Journal of Psychopharmacology* A29, abstract 113

18. Healy D (1993). The psychological treatment of insomnia. *Irish J Psychological Medicine* 10, 62.
19. Healy D (1990). A new science of insanity. *New Scientist* 128, 34-38.
20. Healy D (1990). Prescribing rights for psychologists? *Psychologist* 3, 556-557.
21. Healy D (1991). The Hamilton Scales. *British Journal of Psychiatry* 158, 877.
22. Healy D (1991). Sounds from the Bell Jar. *British Journal of Psychiatry* 159, 755-756.
23. Todrick A (1991). Imipramine and 5HT reuptake inhibition. *Journal of Psychopharmacology* 5, 263-267. (ed D Healy).
24. Healy D (1991). Symposia summaries. *J Psychopharmacology* 1, 437-438.
25. Healy D (1992). The Diagnosis of Depression. *Human Psychopharmacology* 7, 154.
26. Lynch T & Healy D (1992). In Conversation with Tom Lynch *Psychiatric Bull* 16, 65-72.
27. Healy D (1992). Psychopharmacology for the psychotherapist. *Human Psychopharmacology* 7, 68.
28. Healy D (1992). The Scientific Basis of Psychiatry. *British Journal of Hospital Medicine*.
29. Healy D (1992). The indemnification of psychopharmacology. *BAP Newsletter Aut* 1992.
30. Healy D, Waterhouse A M (1992). Reactive rhythms, endogenous clocks and non-specific drugs. *J Psychopharmacology, Abstracts of Ann Meeting 1992, A* 29.
31. Healy D (1993). Grangegorman. *Irish Journal of Psychological Medicine* 10, 130-131.
32. Lader M, Healy D et al (1992). The Medical Management of Insomnia in General Practice. *Royal Society of Medicine, Round Table Series* no 28.
33. Healy D (1993). Grangegorman. *History of Psychiatry* 4, 297-298.
34. Healy D (1992). The Beta-Adrenergic Receptors. *Human Psychopharmacology* 7, 357.
35. Healy D (1993). The Aspirin Wars. *BAP Newsletter Spring* 1993.
36. Healy D (1993). Matching the Drug to the Patient's Needs. The prescription of hypnotics. *Prescriber* 4, 12, 36-45.
37. Healy D (1993). Oedipus at Delphi. *British Journal of Psychiatry* 163, 119 - 121.
38. Healy D (1993). *Human Psychopharmacology: Materials and Methods Volume 4. Human Psychopharmacology* 8, 223.

39. Healy D (1993). Beyond the Receptor: the role of Molecular Biology in Psychopharmacology. *Journal of Psychopharmacology* 8, 69-70.
40. Healy D (1994). Human Psychopharmacology: Materials and Methods Volume 4. *British Journal of Psychiatry* 164, 428-429.
41. Healy D. (1993) 'Make Believes' in Psychiatry or the Perils of Progress. *Human Psychopharmacology* 8, 448.
42. Healy D (1993). Brain Dead, Brain Absent, Brain Donor. *Irish Journal of Psychological Medicine* 10, 170-171.
43. Healy D (1993). The psychological treatment of insomnia. *Irish J of Psychological Medicine* 10, 62.
44. Healy D (1994). The Psychological Management of Schizophrenia: Problems and Opportunities. *Br J Psychiatry*, Royal Coll Psychiatrists Annual Meeting 1994.
45. Harborne G, Healy D, Watson F L, Groves L (1993). The neuropsychological effects of ketamine: the dog that didn't bark. *J Psychopharmacol*, Abstracts BAP Ann Meet A19.
46. Pasteur M-A L, Watson F L, Healy D (1993). The cognitive effects of paroxetine in healthy and depressed elderly subjects. *J Psychopharmacol*, Abstracts Ann Meet A18.
47. Healy D (1994). La Mettrie: Medicine, Philosophy and Enlightenment. *Irish J Psychological Med* 11, 50.
48. Healy D (1994). Chronic Fatigue Syndrome. *J Psychopharmacology* 8, 191.
49. Healy D (1994). Psychobiology & cognitive therapy of the neuroses. *J Psychopharmacol* 8, 279.
50. Healy D (1994). Listening to Prozac (Kramer versus Kramer). *Psychological Medicine* 24, 1048-1050.
51. Wilkinson G, Fahy T, Russell G, Healy D, Marks I, Tantam D, Dimond B (1995). Case reports and confidentiality. *British Journal of Psychiatry* 166, 555-558.
52. Nakielny J, Healy D (1994). The fluoxetine and suicide controversy. *CNS Drugs*, 2, 252-254.
53. Healy D (1994). Beyond the receptor; the significance of gene expression for psychopharmacology. *J Psychopharmacology* 8, 69-70.
54. Healy D (1995). Biology of Depressive Disorders. *Human Psychopharmacology* 10, 68.
55. Healy D (1994). Cocaine. *Drugs of Abuse: A comprehensive series for clinicians*. *Human Psychopharmacology* 9, 447.
56. Healy D (1995). From fasting saints to anorexic girls. *Irish J Psychological Medicine* 12, 41-42.



57. Healy D. (1995). Cocaine: Physiological and Physiopathological Effects. Human Psychopharmacology 10, 163.
58. Healy D (1995). Clinical Evaluation of Psychotropic Drugs. Human Psychopharmacology 10, 249.
59. Healy D (1994). Psychobiology and cognitive therapy of the neuroses. Journal of Psychopharmacology 8, 279.
60. Healy D (1995). The proscription of prescription. The Psychologist April, pp 223 et seq.
61. Healy D (1995). Current insights on obsessive-compulsive disorder. Human Psychopharmacology 10, 248.
62. Healy D (1995). Critical Issues in the Treatment of Affective Disorders. Human Psychopharmacology 10, 357.
63. Healy D (1995). Bipolar affective disorder. in Mental Health. A Technical Document produced by the Welsh Health Gain Panel of Review. Ed Farmer A, p 145-156.
64. Healy D (1995). Clinical Psychopharmacology. Human Psychopharmacology 10, 495.
65. Healy D (1995). Clinical Measurement in Drug Evaluation. Human Psychopharmacology 10, 494.
66. Watson F, Harborne CG, Tipper ST, Healy D (1995). Ketamine, negative priming and the breakdown of integrative perceptual processes. J Psychopharmacol 9, 3, A3, abstract 170.
67. Johnstone F, Rickard I, Healy D (1995). The costs of psychotropic medication. British Journal of Psychiatry 167, 112-113.
68. Healy D (1995). Alzheimers and Parkinson's disease. J Psychopharmacology 10, 257.
69. Healy D (1996). The NMDA receptor. J Psychopharmacology 10, 171.
70. Healy D (1996). Drugs and Addictive Behaviour. J Psychopharmacology 10, 257.
71. Healy D (1996). Biological Psychiatry. Human Psychopharmacology 11, 429.
72. Healy D (1996). Handbook for the Treatment of the Seriously Mentally Ill. Human Psychopharmacology 11, 527.
73. Guest JF, Hart WM, Cookson RF, Lindstrom E (1996). Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. British J Medical Economics 10, 59-67. Based on Delphi panel contributions for DH and others.
74. Healy D (1997). In Brodie's shadow. J Psychopharmacology 11.
75. Healy D (1997). Narrative, history and accuracy. J Psychopharmacology 11, 95.

76. Healy D (1997). Blues in the Night. The Nursing Times. April 9th.
77. Healy D (1997). Clinical Handbook of Psychotropic Drugs. J Psychopharmacol 11, 96.
78. Healy D (1997). Reply to AJ Goudie – what is the clinical significance of the discontinuation syndrome seen with clozapine? J Psychopharmacology 14, 191.
79. Healy D (1997). Architects of the Great Depression. Times Higher Ed Suppl June 18<sup>th</sup>
80. Healy D (1997). Child and adolescent clinical psychopharmacology. Human Psychopharmacology 12, 168.
81. Healy D (1997). Pleasure and Quality of Life. Human Psychopharmacology 12, 168.
82. Healy D (1997). History of Psychiatry. Human Psychopharmacology 12, 398.
83. Healy D (1998). Deconstructing Psychopathology. Psychological Medicine 28, 744-745.
84. Healy D (1998). The Invention of Depression. Openmind
85. Healy D, Farquhar G, Watson F, Tipper S (1998). Varieties of hallucinatory experience and their neural basis. J Psychopharmacology 12, A2, abstract 5.
86. Tansey EM, Christie DA, Reynolds LA (1998). Wellcome Witnesses to Twentieth Century Medicine. Vol2. Drugs in Psychiatric Practice. Pp 133-205.
87. Mortimer A, Healy D, Gray R, Peveler R, Pratt P, Sharma T, Turner T (1998). Consensus statement on schizophrenia standards in care for maintenance therapy and poorly responding/treatment intolerant patients. Int J Neuropsychopharmacology.
88. Healy D, Savage M, Thomas P (1998). Abusive Prescribing. Openmind September.
89. Healy D (1998). Conquering Schizophrenia. Human Psychopharmacology 13.
90. Hirschfeld RM, Keller M, Bourgeois M, Baldwin DS, Healy D, Humble M, Kasper S, Montgomery S (1998). Focus on social functioning in depression. Int J of Psychiatry in Clinical Practice 2, 241-243.
91. Healy D (1998). The Management of Depression. Int J Psychiatry in Clin Pract 2, 313.
92. Healy D (1999). Staying Sane. Psychological Medicine 29, 496-498.
93. Healy D (1998). From Placebo to Panacea: Putting Psychiatric Drugs to the Test. Human Psychopharmacology 13, 591.
94. Healy D (subm). Noradrenaline, serotonin and social functioning: an overview of implications for the patient. Psychiatric Services.
95. Healy D (1999). Differential effects of reboxetine and fluoxetine on social functioning: implications for treatment. In Depression and Social Functioning: the role of reboxetine,

- a new selective noradrenaline reuptake inhibitor. Pennine Press, Macclesfield, pp 49-54.
96. Healy D (1999). The clinical and theoretical significance of differences between reboxetine and fluoxetine on measures of social functioning. In *Improving Social Functioning Through Effective Antidepressant Therapy: the role of reboxetine, a selective noradrenaline reuptake inhibitor*. Pennine Press.
97. Healy D (1999). The Discovery of the Antidepressants. In *Depression and Social Functioning: the role of reboxetine, a new selective noradrenaline reuptake inhibitor*. Pennine Press, Macclesfield pp 4-10.
98. Boardman A, Healy D (1999). Suicide rates in primary care affective disorders. *J Psychopharmacology* 13, abstract P140.
99. Healy D (1999). Trouble in the Freudian Gulf. *British Medical Journal* 318, 949.
100. Healy D (1999). On the History of Lunacy. *British Medical Journal* 319, 63.
101. Healy D (1999). History of the Treatment of the Schizophrenias. *Current Opinion in Psychiatry* 12, S-135-3, p 281.
102. Healy D (1999). Prescriptions, licences and evidence: a reply. *Psychiatric Bulletin* 23, 442-443.
103. Hirschfeld RM, Montgomery SA, Keller M, Kasper S, Schatzberg A, Moller HJ, Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois ML (2000). Social functioning in depression. *J Clinical Psychiatry* 61, 268-275.
104. Healy D (1999). Loss of anxiety and increased aggression in a 15 year old boy taking fluoxetine. *Psychopharmacology* 13, 421.
105. Healy D (2000). The Evolution of Hypnotism. *British Medical Journal* 320, 1015.
106. Healy D (2000). Sitting on it. Feature on Drug-induced akathisia. *Openmind*, March p 18.
107. Healy D (2000). Drugs, therapy, and professional power: Problems and pills *Journal of the History of the Behavioral Sciences* 36: 58-59
108. Healy D, Langmaak C, Savage M (2000). Suicidio en el curso del tratamiento antidepresivo. *Revista de Toxicomanias* 25, 4, 31-40.
109. Healy D (2000). Medicating Schizophrenia. *J Nervous & Mental Disease* 188, 717-719.
110. Healy H, Cattell D, Tranter R, Jaffar K, Healy D (2000). Better than Well on antidepressants. *J Psychopharmacology* 14, 3, abstract PC22.
111. Healy D (2000). Antidepressant associated suicidality. *J Psychopharmacology* 14, 3, abstract PC23.

112. Healy D (2001). From neuroplegics, through neuroleptics to antipsychotics. *World J Biological Psychiatry* 2, 15, 167S.
113. Healy D (2001). When Interests Conflict. *Pharmaceutical Executive*, Aug p 98.
114. Healy D (2001). Have drug companies hyped social anxiety disorders to increase sales? Yes. Marketing hinders the discovery of long-term solutions; Response from David Sheehan. *Western Journal Medicine* 175, 364-365.
115. Berrios GE, Healy D (2002). How Tainted has Medicine Become? *Lancet* 359, 1775-1776.
116. Healy D (2002). SSRIs and deliberate self-harm. *British Journal of Psychiatry* 180, 547-548, with replies from Pfizer and Glaxo SmithKline.
117. Healy D (2002). SSRI withdrawal: how to avoid problems. *The Prescriber* 13, 91-92.
118. Serlin D, Healy D (2002). Me, Myself and SuperMe. An interview with David Healy. *Cabinet*, Fall issue, pp 75-78.
119. Healy D (2002). Mad in America. *Mental Health Today*, December p 40.
120. Healy D (2003). Pharmaceutical Ethics. *Mental Health Today* Feb, p 34.
121. Shepherd M, Healy D (2003). Psychopharmacology: Specific and Non-Specific. In *Epidemiologia e Psichiatria Sociale* 12, 22-43.
122. Translation from Delay JM, Deniker P, Harl JM. (1952/2003). The psychiatric use of a selective centrally acting phenothiazine (RP 4560). *Annales Medico-Psychologiques*.
123. Translation from Deniker P, Sempe J-C (1967/2003). Psychopathic Personalities. An attempt at a structural definition. *L'Encephale* 56, 5-32.
124. Translation from Deniker P (1969/2003). Hysteria with minimal symptoms. *Confrontations Psychiatriques* 4, 87-98.
125. Translation from Deniker P (1975/2003). Who invented the Neuroleptics? *Confrontations Psychiatriques* 13.
126. Translation from Deniker P, Ginestet D (1975/2003). The psychological effects of the neuroleptics. *Confrontations Psychiatriques* 13,
127. Translation from Deniker P, Colonna L, Loo H, Petit M (1979/2003). Pharmacopsychoses and the 'Deficit' syndrome. *L'Evolution Psychiatrique* .
128. Healy D (2003). Agensi zivotnog stila. *Vreme*, March 28<sup>th</sup>, pp 36-40.

129. Healy D (2003). A l'heure des antidépresseurs. *Sciences Humaines* 138, May, 28-31.
130. Healy D (2003). The Hour of our Death. *British Medical Journal* 327, 230.
131. Healy D (2003). Madness Explained. *The Independent Magazine*, Saturday 10<sup>th</sup> August page 22.
132. Healy D (2003). Inside the Company Mind. *OpenMIND*.
133. Healy D, Harris M, Chandran S, Chakraborty N (2003). Mood-Stabilisers: Impact on Clinical Practice. *Journal of Psychopharmacology* 17, A 46
134. Healy D (2002). Are concerns about the ethics of placebos a stalking horse for other issues? *American Journal of Bioethics* 2, 17-19. Commentary on Miller F, Brody H, What makes placebo-controlled trials unethical? (PA- R)
135. Healy D, Harris M, Tranter R, Austin R, Gutting P, Jones-Edwards G, Roberts AP (2003). Suicide in the Course of the Treatment of Schizophrenia. *J Psychopharmacol* 17, E47.
136. Do SSRIs increase the risk of suicide? Correspondence from Drs Rihmer and Benazzi, with reply. *Psychotherapy and Psychosomatics* 2003, 72, 357-360.
137. Do SSRIs increase the risk of suicide? Correspondence with Drs P Casey, Painuly and Basu with replies from DH. *Psychotherapy & Psychosomatics* 2004, 73, 260-264
138. Healy D (2003). Conspiracy of Consensus. *Mental Health Today*, Nov, 27-31.
139. Healy D (2004). The impact of psychopharmacology on psychiatry and society. *European Psychiatry* 19 suppl 1, Abstract 48.05, page 28.
140. Healy D, Aldred G (2004). Death, Dependence and Deception. *Journal of Psychopharmacology* 18, 285-287.
141. Healy D (2004). In the Balance. Treating Young People with Psychotropic Medication. *Young Minds* 70, 20-21.
142. Healy D (2004). The impact of psychopharmacology on psychiatry and society. *European Psychiatry* 19, suppl 1, page 28, Abstract S48.05.
143. Herxheimer A et al (2004). Open letter to Annette King, Minister of Health, New Zealand. *British Medical Journal* 329, 51.
144. Healy D (2004). Prozac. Les bonnes fortunes d'une molécule. L'enfance turbulente de la star des antidépresseurs. *La Recherche hors Série* August 16<sup>th</sup> 12-19.
145. Healy D (2004). ISRS. Un risque trop vite effacé. La littérature médicale a occulté la risque suicidaire lié aux antidépresseurs ISRS. *La Recherche hors Série* August 16<sup>th</sup> 24-27.

146. Aldred G, Healy D (2004). Antidepressants and the risk of suicide. *British Medical Journal* 329, 461.
147. Healy D (2004). Hey, this new drug – it's to die for... *The Times Higher Education Supplement*, September 10<sup>th</sup>, 20-21.
148. Healy D (2004). Transparency and trust. *British Medical Journal* 329, 1345.
149. Healy D (2005). With this Prize, everyone will be a winner. Review of *Strong Medicine*. *Times Higher Education Supplement* July 8<sup>th</sup> p 27.
150. Healy D (2005). *Essential Evidence Based Medicine*. *Times Higher Education Supplement*.
151. Healy D (2005). Do selective serotonin reuptake inhibitors cause suicide? *British Medical Journal* 330, 1148.
152. Fergusson D, Doucette S, Healy D, Shapiro S (2005). Do selective serotonin reuptake inhibitors cause suicide? *British Medical Journal* 330, 1150.
153. Healy D (2005). The First Cut. A review of *The Lobotomist*. *Nature Neuroscience* 8, 695.
154. Healy D (2005). In Open Water. A review of *The Trouble with The Drug Companies*. *Monash Review of Bioethics* 24, 58-59.
155. Healy D (2005). Concerns about conflict of interest. *J Psychopharmacology* 19, 314-315.
156. Healy D (2005). Prozac on the Couch. *J of Sex & Marital Therapy* 31.
157. Healy D (2005). Manufacturing consensus: More important than manufacturing drugs. *Neuropsychopharmacologia Hungarica* 7, suppl 1, 33-34.
158. Healy D (2005). The Drug Trial. *Monash Review Bioethics* 24, 4, 50-55.
159. Healy D (2006). Obituary: Roland Kuhn. *History of Psychiatry* 16
160. Healy D (2006). Poles Apart. *New Scientist* 15<sup>th</sup> April, 38-41.
161. Healy D, Ghaemi N (2006). The best hysterias; the newest mania. *PLoS Medicine*, [plosjournals.org/perlserv/?request=readresponse&doi=10.1371/journal.pmed.0030185](http://plosjournals.org/perlserv/?request=readresponse&doi=10.1371/journal.pmed.0030185)
162. Healy D (2006). This new pill will fix it ... *The Medicalization Debate*. *Hospital Doctor* June 1<sup>st</sup>, p 23, with response by R Barker.
163. Healy D (2006). Hasty bolt down the aisle or well-considered union. *Academic freedom and commercialism*. *Times Higher Education Supplement* August 18<sup>th</sup> with response by Robert Jackson MP.

164. Translation from Delay J, Deniker P (1952/2006). 38 Cas de psychoses traitées par la cure prolongée et continue de 4560 RP. C.R.Congrès Méd Alién Neurol France 50, 497-502.
165. Translation from Delay J, Deniker P, Ropert R (1955/2006). Etude de 300 dossiers de maladies psychotiques traités par la chlorpromazine en service fermé depuis 1952. Encéphale 528-535.
166. Translation from Delay J, Deniker P, Garnier Mlle (1951/2006). Une grande amnésie de guerre. Ann Méd Psychol 109, 544-551.
167. Translation of Delay J, Deniker P, Green A (1959/2006). Essai de description et de définition psycho-pathologique des parents de schizophrènes. In Second International Psychiatric Congress, Symposium on the Family Milieu of Schizophrenics, Zurich, Sept 4<sup>th</sup> 1957.
168. Translation from Delay J, Deniker P, Volmat R, Alby J-M (1956/2006). Une demande de changement de sexe: le trans-sexualisme. Encéphale 45, 41-80.
169. Translation from Delay J, Deniker P, Lempérière T, Benoit J-C (1954/2006). Histoire d'un travesty: L'éonisme. Encéphale 43, 385-398.
170. Translation from Deniker P, Quintart JC (1961/2006). Les signes pseudo-névrotiques dans les formes limites de la schizophrénie. Encéphale 50, 307-323.
171. Translation from Delay J, Deniker P, Dalle B (1966/2006). Les syndromes hallucinatoires idiopathiques chroniques de l'adulte. Encéphale 55, 79-94.
172. Healy D (2007). Panic Diaries: A Review. Bull History of Medicine 81, 902-904.
173. Healy D (2007). One Flew over the Conflict of Interest Nest. World Psychiatry 6, 26-27; Invited response to Fava G, Financial conflicts of interest in psychiatry.
174. Healy D (2007). Media care and patient pressure. J Psychopharmacology 21, 668-670.
175. Healy D (2007). The Cult of Pharmacology. Perspectives in Biology and Medicine 50, 467-471.
176. Healy D (2007). Antidepressant medication and other treatments for depressive disorders: A CINP Task Force Report. Int J Neuropsychopharmacol 10, S179-181.
177. Antonuccio D, Healy D (2008). The researcher's credo. BMJ 336, 629.
178. Healy D (2008). SSRIs have a specific risk among antidepressants to cause suicidality. Int J Neuropsychopharmacology 11, supplement 1, p 4.
179. Healy D (2008). Paediatric bipolar disorder. Australasian Psychiatry 16, 295.

180. Healy D (2009). Psychiatry and the pharmaceutical industry. *Br J Psychiatry* 194, 85.
181. Healy D, Charlton BG (2009). Electroshock in Zen and the Art of Motorcycle Maintenance – Fictional not factual. *Medical Hypotheses* 72, 485-486.
182. Kraepelin E, Freud S (2009). Kraepelin-Fraud syndrome. *Medical Hypotheses* 72, 378-380.(Editorial Responsibility).
183. Healy D (2009). On Speed. *Journal of Attention*.
184. Healy D (2009). How marketing created the illusion antidepressants work. *Italian J of Psychopathology* 15, 113-114.
185. Healy D (2009). Psychedelics. *Bulletin of the history of Medicine*
186. Healy D (2009). Amphetamine's Missing History. *Chemical Heritage* 27, p 45.
187. Healy D (2009). Dilemmas of Mind and Soul. *Times Higher Ed Supp*, May 28<sup>th</sup>.
188. Healy D (2009). Not the Last Word. *BMJ* 339.
189. Healy D (2009). Spontaneous Publications and Academic Miscarriages (SPAM), *BMJ* 339: b4293, p 933.
190. Healy D (2009). Happy Pills in America. *Social History of Medicine*  
doi:10.1093/shm/hkp083
191. Healy D (2009). Psychedelic Psychopharmacotherapy. *Bulletin of the History of Medicine*
192. Healy D (2009). Obsession. *Bulletin of History of Medicine*.
193. Healy D, Herxheimer A, Menkes D (2010). Induction of violence by psychotropic drugs: signal detection. *Internat Soc of Pharmacovigilance 9th Annual meeting*, poster abstract 213 *Drug Safety* 2009;32: 964.
194. Healy D (2010). Treatment induced stress syndromes. *Medical Hypotheses* 74, 764-768 doi:[10.1016/j.mehy.2010.01.038](https://doi.org/10.1016/j.mehy.2010.01.038)
195. Kraepelin E, Freud S (2009). Kraepelin-Fraud syndrome. *Medical Hypotheses*. 72, 378-380.
196. Parker G, Fink M, Shorter E, Taylor MA, Akiskal H, Berrios G, Bolwig T, Brown WA, Carroll B, Healy D, Klein DF., Koukopoulos A, Michels R, Paris J, Rubin RT, Spitzer R, Swartz C (2010) Reply to Kocsis letter. *Am J Psychiatry* 167, 1534-1535.
197. Entrevista e David Healy. *VERTEX Rev. Arg. de Psiquiat.* 2010, Vol. XXI: 459 – 461.



198. Healy D, Mangin D, Mintzes (2010). Risky Business. Hastings Center Reports, July-August P 7.
199. Urato AC et al (2011). SSRIs and Pregnancy: Failing to Warn Patients of Risks. Obstetrics and Gynecology.
200. Mangin D, Healy D, Mintzes B (2011). Paroxetine is associated with malformation during pregnancy. BMJ 343:d5060 doi: 10.1136/bmj.d5060
201. Healy D (2011). The strangeness of normal things. Times Higher Ed Supp August.
202. Healy D (2011). What is Madness? Times Higher Ed Supp October.
203. Healy D (2012). Pharmaceutical Selves. Transcultural Psychiatry.
204. Healy D (2011). The Man who got inside their heads. Times Higher Education Supplement, December
205. Healy D (2012). Hard times are not happy times. Times Higher Education Supplement, January
206. Healy D (2013). Comment for Evidence Based Mental Health on "Talaslahti T, Alanen HM, Hakko H, Isohanni M, Häkkinen U, Leinonen E. Mortality and causes of death in older patients with schizophrenia. Int J Geriatr Psychiatry. 2012; 27:1131-7.
207. Healy D (2013). Bad Pharma. London Review of Books
208. Healy D (2013). Our Necessary Shadow. The Literary Review
209. Herder M, Doshi P, Healy D et al FDA to begin releasing clinical study reports in pilot programme. BMJ 2018; 360 doi: <https://doi.org/10.1136/bmj.k294>
210. Healy D. (2020). Love and the Dream Drugstore. Indian Journal of Medical Ethics DOI:10.20529/IJME.2020.029.
211. Healy D. (2021). How Modern Medicine became Dangerous. Neoliberalism isn't what you think it is.  
[https://iai.tv/articles/how-modern-medicine-became-dangerous-aid-1834?\\_aid=2020](https://iai.tv/articles/how-modern-medicine-became-dangerous-aid-1834?_aid=2020)
212. Healy D (2022). Towards a Zombie Psychiatry. Indian J of Medical Ethics DOI: 10.20529/IJME.2022.014
213. Healy D (2022). Drowning in Drugs. Big Pharma is Making us Sicker  
[https://iai.tv/articles/drowning-in-drugs-aid-2161?utm\\_source=Institute+of+Art+and+Ideas&utm\\_campaign=377fde9813-EMAIL\\_CAMPAIGN\\_2022\\_06\\_22\\_04\\_03&utm\\_medium=email&utm\\_term=0\\_33593fe9fa-377fde9813-47026957](https://iai.tv/articles/drowning-in-drugs-aid-2161?utm_source=Institute+of+Art+and+Ideas&utm_campaign=377fde9813-EMAIL_CAMPAIGN_2022_06_22_04_03&utm_medium=email&utm_term=0_33593fe9fa-377fde9813-47026957)

## INVITED PRESENTATIONS

1. Functional variations in platelet rich plasma - Irish Blood Club, September 1981
2. A serotonin receptor assay - Irish Blood Club, Sept 1982
3. The role of adrenergic receptors in mental illness - Irish Neurosciences Group, March 1983.
4. Ambiguities in the uptake of 5HT in platelets from both depressed patients and from controls - Irish Neurosciences Group, October 1984.
5. Two Crows sitting on a Fence - Irish Neurosciences Group, March 1985.
6. Platelet & Neuroendocrine studies in Depression - Irish Neurosciences Group, March 1987.
7. Biochemical Markers in Depression - Pontedilegno Workshop on Membrane Mechanisms in Synaptic Transmission, June 1982 (poster).
8. The Uptake of Serotonin in Depression - Royal College of Psychiatrists, July 1983.
9. Is 5HT induced platelet aggregation a useful index to depression? - British Pharmacological Society, September 1983.
10. Serotonergic Markers in Depression - Brain and Behaviour Workshop, Zuoz, January 1984 (poster).
11. Abnormalities in the Circadian Regulation of 5HT Uptake into the Platelets of Depressed Persons - 14th CINP, Florence, June 1984.
12. Use of a Microcomputer to rate Depression in a West of Ireland Population - 14th CINP, Florence, June 1984 (poster).
13. Rhythm and Blues - Invited Speaker to Symposium on Recent Advances in Biological Psychiatry, Queens University, Belfast, September 1985.
14. Normal and Abnormal Variations in Platelet 5HT Uptake from Control and Depressed Populations - Royal College of Psychiatrists, November 1985.
15. One Hundred and One Uses for a Dead Psychiatrist. Invited Speaker at a Symposium on Animal Models of Depression, BAP Summer Meeting, Cambridge 1987.
16. Mourning, Melancholia and Mood-Altering Drugs - Invited Speaker at a BAP Symposium on Current Developments on Psychopharmacology, in Birmingham, Spring 1988.
17. The effect of treatment with and withdrawal from antidepressants on platelet 3H Imipramine binding in volunteers. BAP Cambridge 1988.
18. Rhythm and Blues - Invited Speaker at a BAP Symposium "Thirty Years Since Imipramine" in Galway, September 1988.

19. Plasma noradrenaline (NA), adrenaline (A) and DHPG levels in depression before and after clonidine. Spring Quarterly Meeting of Royal College of Psychiatrists, Galway, 1990.
20. Antidepressant induced suicidal ideation. Free Communications BAP Annual General Meeting, York 1991.
21. Acid Alpha-1 Glycoprotein levels in Depression. Free Communications, BAP Annual General Meeting, York 1991.
22. Altered States of Consciousness: Phenomenology and Pharmacology. BAP Annual General Meeting York 1991, Invited Speaker.
23. Clinical Chickens and Marketing Eggs. BAP Spring Meeting, North Wales 1992, Invited Speaker.
24. Endogenous Rhythms and Reactive Clocks. BAP Annual General Meeting Cambridge 1992, Invited Speaker.
25. Neuropsychology, Pharmacopsychology and Schizophrenia. Second International Symposium on Schizophrenia, Maastricht Nov 1992.
26. The Enigma of Irish Psychiatry. European Association for the History of Psychiatry, Third General Meeting London August 1993.
27. The Role of Drug Treatment in Psychiatric Rehabilitation. Third World Congress for Psychosocial Rehabilitation, Dublin Sept. 1993.
28. The Enigma of Irish Psychiatry. Third World Congress for Psychosocial Rehabilitation, Dublin Sept. 1993.
29. Altered Circadian Rhythms and Depression. European Society for Chronobiology 9th Annual Meeting, Bath, September 1993.
30. The Marketing of Psychotropic Drugs: How the Industry Gets it Right. BAP Winter Meeting, Nov 1993.
31. Healthy Volunteer Research in Psychopharmacology. Milford Symposium IV, Univ of Surrey Guildford January 1994.
32. Psychiatry, Psychotherapy and the Future of Mental Health Services in Primary and Secondary Care. Royal Society of Medicine, Section of General Practice. Jan 1994.
33. Human Psychopharmacological Research with Healthy Volunteers: Problems and Opportunities. BAP Spring Meeting, Birmingham 1994.
34. The Psychological Management of Schizophrenia: Problems and Opportunities. Royal College of Psychiatrists Annual General Meeting Cork 1994.

35. Psychotropic Medication and compliance: a patient-centred approach. Twentieth European Conference on Psychosomatic Medicine, Gent, August 1994.
36. The Industrialisation of Psychiatric Language. Royal College of Psychiatrists. Winter Meeting, Glasgow, 1995.
37. The Role of Abuse in Psychiatric Presentations. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Port Douglas Preconference Symposium, May 1995.
38. The psychotherapy of psychosis. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Cairns, May 1995.
39. The evaluation of psychotherapies. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Cairns, May 1995.
40. Horizons in addiction therapy. Addiction Section of Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Hamilton Island May 1995.
41. The Discovery of the Antidepressants to the History of Medicine Department, University of Toronto, October 1995.
42. The Influence of Pharmaceutical Developments on Psychiatric Nosology, To the Clarke Institute of Psychiatry - Visiting Lecturer, October 1995.
43. Negative Priming and Psychosis, CINP Melbourne, June 1996.
44. The Invention of Antidepressants, AEP and Royal College of Psychiatrists Meeting London, July 1996.
45. Negative priming in healthy volunteers after neuroleptics, minor tranquillisers and ketamine and in treated and untreated psychotic subjects. ACNP, Dec 1996 (poster).
46. Rhythm & Blues. British Psychological Society, Winter Meeting, London Dec 1996.
47. Innovation in Drug Treatment. NHS Executive (West Midland), Commissioning and Provision of Services for the Severely Mentally Ill. Birmingham March 1997.
48. Wellcome Witness Seminar on The Impact of Psychopharmacology on Psychiatry, March 1997 (serial contributions).
49. The Church, Nationalism and Mental-Illness in Early Twentieth Century Ireland. Wellcome Trust Specialist Seminar on Asylums, Trinity College Dublin June 30th 1997.
50. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. Satellite Symposia at Royal College of Psychiatrists Summer Meeting, Bournemouth 1997
51. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. Satellite Symposia at BAP Annual Meeting Cambridge 1997

52. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. ECNP Annual Meeting Vienna, Sept 1997
53. Methods of Rating Depression in Clinical Trials. 7th Japanese Clinical Neuropharmacology Association meeting. Tokyo, Nov 1997.
54. The Invention of Depression. Scottish Division of Royal College of Psychiatrists, Winter 1998.
55. Does Technology Drive History. Enhancement Technologies Research Group Seminar, University College London, Feb 1998.
56. New Drugs and Old Problems, Mind Conference, London, April 1998.
57. Social Functioning in Depression. Scandinavian Society for Psychopharmacology, Copenhagen, April 1998.
58. Reboxetine, the first selective norepinephrine reuptake inhibitor. American Psychiatric Association Meeting, Toronto, June 1998, New Research Symposium abst NR 228.
59. Physical Treatments in Psychiatry Before 1948. Royal College of Psychiatrists Annual General Meeting, Belfast June 1998.
60. Hallucinations and Psychopharmacology, Invited Symposium Speaker, BAP Annual Meeting, Cambridge July 1998.
61. The History of the Antidepressants, in XX1st CINP Meeting, Glasgow July 1998.
62. The Role of Consensus Statements on Psychotropic Drugs in Therapeutics in Learning Disabilities Conference, Nottingham November 1998.
63. The Antidepressant Project. American Psychopathological Association Meeting, New York, March 1999.
64. The Antidepressant Era, The Annual Raths-Steiger lecture, Zurich, June 1999.
65. Modelling suicide risk in primary care primary affective disorders. British Association of Psychopharmacology Annual Meeting Harrogate July 25<sup>th</sup> 1999 (poster).
66. History of the Treatment of the Schizophrenias, World Psychiatric Association meeting History of Psychiatry Section Symposium, Hamburg August 1999.
67. The rational basis for prescribing antidepressants. European College of Neuropsychopharmacology London, Sept 1999.
68. Neuroleptic Discontinuation Syndromes. United Kingdom Psychiatric Pharmacists Annual Meeting, November 1999.
69. The expansion of the therapy industry in North Wales: 1896 and 1996 compared. St David's Day Conference – Health and Medicine in Wales.

70. Discovery and Development of the Antidepressants: What the History Books won't tell you. McLean Hospital Psychopharmacology Service, Harvard University Boston, March 24<sup>th</sup> 2000.
71. Psychopharmacology and the Disease Concept. Oslo Department of Psychiatry Annual Psychiatry Symposium, March 31<sup>st</sup> 2000.
72. Beyond the Disease Concept. Oslo Department of Psychiatry Annual Psychiatry Symposium, March 31<sup>st</sup> 2000.
73. Antidepressant Associated Suicidality (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000.
74. Antidepressant Associated Suicidality (poster). The British Association of Psychopharmacology meeting in July 2000
75. Antidepressant Associated Suicidality (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
76. Better than Well on Antidepressants (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000,
77. Better than Well on Antidepressants (poster). The British Association of Psychopharmacology meeting in July 2000
78. Better than Well on Antidepressants (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
79. The Social Adaptation Self-evaluation Scale: Effects of antidepressants (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000.
80. The Social Adaptation Self-evaluation Scale: Effects of antidepressants (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
81. Let Them Eat Prozac. Centre for Freudian Analysis & Research, London, October 2000.
82. The Interface between Psychopharmacology & Society: 1952-2002. In Looking Back, Looking Ahead. Psychiatry in the 21<sup>st</sup> Century: Mental Illness & Addiction. 75<sup>th</sup> Anniversary of the U of Toronto's Dept of Psychiatry, November 2000.
83. Psychopharmacology and the Silence of the Cemetery. Grand Rounds Westchester Division, Cornell University, December 2000.
84. The Creation of Depression. Eric T Carlsson Memorial Grand Rounds, Payne Whitney Division, Cornell University, December 2000.
85. Psychotropic Drugs & The Social Contract. Richardson Research Seminar Institute for the History of Psychiatry, Cornell University, December 2000.
86. Psychopharmacology and The Government of the Self. Centre Nationales de Research, Paris, February 2001.

87. The Rise of Corporate Psychiatry. Departments of Psychiatry and Bioethics, University of Minnesota, April 2001.
88. Treating More Patients than Ever Before. 6<sup>th</sup> Hannah International Symposium, April 2001, Toronto.
89. Good Science or Good Business, SSRIs & Suicide. Joint Centre for Bioethics, University of Toronto, April 19<sup>th</sup> 2001.
90. The History of Antidepressant Therapies. Korean Society for Psychiatry, April 27<sup>th</sup> 2001, Seoul.
91. Making an Antipsychotic. First Greek Society of Psychophysiology Meeting, Thessalonika, June 2001.
92. From Neuroleptics to Antipsychotics. World Federation of Biological Psychiatry. July 2001, Berlin.
93. The Drug Dependence at the Heart of European Social Democracy. Royal College of Psychiatrists & World Psychiatric Association Meeting, July 2001, London.
94. Reshaping Personhood and Identity. At Visions of Life, Molecular Politics and Normalisation, Hinxton Hall, Cambridge, July 17<sup>th</sup> 2001.
95. Evidence Biased Psychiatry. BRAF meeting, University College London, September 19<sup>th</sup> 2001.
96. Where Neuroscience and Culture Meet. Robert Mayne Annual Lecture, Trinity College Dublin, September 27<sup>th</sup> 2001
97. What History Teaches Us. Inaugural Meeting of the Irish Psychiatric Association, Kilkenny, October 28<sup>th</sup> 2001.
98. Cognitive Effects of Psychotropic Drugs. UK Psychiatric Pharmacists Annual Meeting, Reading October 2001.
99. National Institutes of Health Symposium: New Frontiers of Biomedical Research 1945-1980; Psychopharmacology & Behavior, Bethesda, Maryland, Oct 29<sup>th</sup> 2001.
100. McLean Hospital Grand Rounds – Treating More Patients than Ever Before, Boston November 1<sup>st</sup> 2001.
101. Harvard Medical Anthropology Program – Psychopharmacology & The Appearances of Science, November 2<sup>nd</sup> 2001.
102. Social Science: 4S Conference – Analysing Tanya Luhman’s In Two Minds, Invited Discussant November 2001.
103. Hidden Effects of Antidepressants. Adverse Reactions to Psychotropic Drugs Meeting, London, November 8<sup>th</sup>.

104. Science and Human Agency: Genes, Drugs and Behaviour. Invited Discussant, Gresham College & The Royal Society, London December 2001.
105. The Appearances of Science – London Medical Sociology Group, January 2002
106. Psychiatry™. The troubled relationship between psychiatry and the pharmaceutical industry. Annual Mind Lecture, Institute of Psychiatry February 2002
107. The Appearances of Science, Bradford University, February 2002.
108. Treating More Patients Than Ever Before, Nottingham, March 2002
109. Science & the Degradation of Psychiatric Care, Invited Plenary Lecture Psychotherapy Section of Royal College of Psychiatrists, Annual Meeting Cambridge April 2002.
110. The Fate of Bipolar Disorders 1900 and 2002 Compared, Yorkshire Section of Royal College of Psychiatrists, April 2002.
111. The New Medical Oikumene. Invited Plenary Lecture, Harvard University Dept of Social Medicine, Workshop on Pharmaceuticals and Globalization. May 2002.
112. The Appearances of Science, University of California, Los Angeles, Dept of Psychiatry, UCLA Medical Classics Lecture, May 2002
113. Evidence Biased Psychiatry, Leading Edge Seminars, Toronto May 2002.
114. Psychopharmacology and the Government of the Self, Public Lecture, Toronto May 2002.
115. Psychopharmacology: What you're not being told. Teesside University Conference – The Fish Ain't Sick, the Water's Dirty, September 2002.
116. Dependence on SSRIs. Addiction Research Forum, Durham, September 2002.
117. This House believes that psychiatry has been compromised by its links with the pharmaceutical industry. Debate in the General and Community Faculty Meeting of the Royal College of Psychiatrists, Newcastle, October 18<sup>th</sup>
118. The Rise of Corporate Psychiatry, Grand Rounds, Ann Arbor, Michigan, October 23<sup>rd</sup> 2002.
119. Psychopharmacology and the Government of the Self. History of Psychiatry Group, Harvard University Faculty Club October 21<sup>st</sup> 2002
120. The Emergence of Corporate Psychiatry Grand Rounds, Cambridge City Hospital. October 29<sup>th</sup> 2002
121. The Corporate Colonisation of the Campus. Queens University, Kingston Ontario, First Annual Lecture on Academic Freedom. November 1<sup>st</sup> 2002.



122. The Silencing of Dissent. Canadian Association of University Teachers' Meeting on Disciplining Dissent Ottawa, November 1-3, 2002.
123. Psychopharmacology in Historical Perspective. History of Psychiatry Group, Cambridge University. November 2002.
124. Drugs – Whose Profit & Whose Loss? Café Scientifique and The Royal Society, Leeds, Nov 18<sup>th</sup>.
125. The not-so-everyday psychopharmacology of everyday nerves. University of Toronto, History of Medicine Conference – the Social Sources of Psychopharmacology, February 25<sup>th</sup> 2003.
126. Risk Societies and the future of psychopharmacology. Dept of Bioethics, University of Toronto, Feb 26<sup>th</sup>, 2003.
127. Brownbag Research Seminars: Grippled by a Python: How Pharmaceutical Companies Control the Medical Marketplace, February 27<sup>th</sup>. York University Toronto
128. That this house believes SSRI treatment causes a significant risk of increased suicidality. Affective Disorders Group, North West, Manchester March 2003.
129. The Creation of Psychopharmacology. Salon International de la Salud, Santiago de Compostella, Spain March 2003.
130. This House believes that Suicide is caused by SSRIs. Irish College of Psychiatrists Dublin March 2003.
131. The Role of New Antipsychotics in Mood Stabilization. Plenary Lecture, General Practice Psychotherapy Association Toronto April 4<sup>th</sup> 2003.
132. Why do we say Doctoring the Data? Robert TM James Memorial Lecture, General Practice Psychotherapy Association Toronto April 3<sup>rd</sup>, 2003.
133. Academic Freedom and your Sex Life. Academic Freedom & The Public Interest, Simon Fraser University, Vancouver, April 25<sup>th</sup>.
134. This House Believes that Antidepressants Cause Dependence. Maudsley Hospital/Institute of Psychiatry, Mental Health Care Debate, July 16<sup>th</sup>, London.
135. Mood Stabilizers: Possible Impact on Service Utilization. British Association for Psychopharmacology – Poster July 2003.
136. Suicide in Schizophrenia. British Association for Psychopharmacology – Poster July 2003.
137. The Construction of the Psychopharmaceutical Marketplace. Plenary Lecture in Vital Politics: Health, Medicine, and Bioeconomics into the 21<sup>st</sup> Century. London School of Economics Sept 2003.

138. The Psychiatric Dance. Theory and Practice of Mental Health Care During the Twentieth Century. U of Amsterdam – Sept 2003.
139. Psychopharmacology and the Government of the Soul. In Stockholm, Swedish Medical Society, Axel and Margaret Ax:son Johnson Foundation, Seminar: From Hysteria to Depression: Modernity & its Discontents. Sept 25<sup>th</sup> 2003.
140. Risk Management: the Way of the future in psychopharmacology. In Stockholm, Swedish Medical Society, Axel and Margaret Ax:son Johnson Foundation, Seminar: From Hysteria to Depression: Modernity & its Discontents. Sept 25<sup>th</sup> 2003.
141. The Construction of the Pharmaceutical Marketplace: Legal Implications. Symposium on Medicine & Industry. 28<sup>th</sup> International Congress on Law & Mental Health Law, Sydney, Sept 2003.
142. Legal Scientism. 28<sup>th</sup> International Congress on Law & Mental Health Law, Sydney, Sept 2003.
143. The Interface between Business and Science. Queensland University of Technology, Guest Lecture, October 2003.
144. Emerging trends in Clinical Litigation. Queensland University of Technology, Faculty of Law. Brisbane, October 2003.
145. Depressed, Bothered and Bewildered. Debate on ABC radio with Ian Hickie, Murdoch University Perth, Australia, October 2003.
146. Shaping the Intimate, Guest Lecture, Murdoch University, Perth, October 2003.
147. Academic Freedom in the New Medical State. University of New Brunswick Academic Freedom Lecture, October 2003.
148. Manufacturing patients, Panel Discussion, University of New Brunswick, October 2003.
149. Psychopharmacology and Freedom. World Mental Health Day, Toronto October 2003.
150. Prozac and Paxil: Fireworks at the medicolegal interface. University of Toronto Faculty of Law Seminar Series, October 2003.
151. The New Language of Marketing. Trent University, Ontario, October 2003.
152. How Pharmaceutical Companies Mould Consciousness. Grand Rounds Neuropsychiatric Institute UCLA, Los Angeles, October 2003.
153. Suicide in the Course of the Treatment of Schizophrenia. Grand Rounds, Harbor-UCLA campus, October 2003.
154. Manufacturing Consensus. Plenary Lecture at Is Psychiatry for Sale, A Mind and Critical Psychiatry Meeting, London, November 17<sup>th</sup>

155. Ghostwriting in the Scientific Marketplace. The political economy of psychiatric drugs and medical authorship. American Anthropological Association Annual Meeting, Chicago, November 19<sup>th</sup> 2003
156. Shaping the Intimate, Bartlett Visiting Professorship, University of Rochester, New York, Nov 22<sup>nd</sup> 2003.
157. Mental Health Service Utilization: 1900 and 2000 Compared. Rochester Psychiatric Institute, Grand Rounds, Nov 22<sup>nd</sup> 2003
158. SSRIs and Suicidal Behavior. Bartlett Visiting Professorship, Workshop, University of Rochester, New York, Nov 23<sup>rd</sup> 2003.
159. The Interface between Academia and Industry. British Association of Pharmaceutical Physicians Annual Meeting, Industry Sponsored Research, Tainted or Unfairly Maligned, Commonwealth Institute, London, January 2004
160. The Fault line in the Drugs Approval System; Risk First, Safety Later, Health Coalition Canada forum, Ottawa, January 28<sup>th</sup> 2004
161. Freud – The Second Coming? What the Antidepressant Story says about Psychoanalysis. Emory University, Atlanta January 2004.
162. The Creation of Depression. Georgia Tech, Atlanta, January 2004.
163. Healy D, Debate: This House Believes that Academic Research in Schizophrenia is in bondage to the pharmaceutical industry. In 12<sup>th</sup> Schizophrenia Annual Winter Workshop, Davos, February.
164. The role of medication in mental health nursing - the Debate. Royal College of Nursing Annual Meeting, Dublin February 2004.
165. How Pharmaceutical Companies Manufacture Cultures. Clinical Trials Research Group, McGill University.
166. Drug Development in Alzheimer's Dementia. Lessons from the History of Drug Development. Johns Hopkins Baltimore March 2004.
167. The impact of psychopharmacology on psychiatry and society. World Psychiatric Association Meeting, Geneva, April 2004.
168. Suicide in the Course of the Treatment of Schizophrenia. American Association for the Advancement of the History of Medicine, Madison Wisconsin April 2004.
169. Marketing Illness. Let Them Eat Prozac. Health Ethics Quarterly Rounds St Boniface Research Centre, Winnipeg May 2004.
170. A conversation with DH. Winnipeg Regional Health Authority, Health Sciences Centre, May 2004.

171. Let Them Eat Prozac, Suicide and Psychotropic Drugs. Nevada State Psychological Association, Annual Conference, Reno Nevada, May 2004.
172. Manufacturing Consensus: The End of Psychiatry as a Science? Scottish Division of Royal College of Psychiatrists, June 2004
173. Schizophrenia: the dangers of current treatments, the need for new approaches. First Horrobin Annual Prize Lecture, London, June 2004.
174. Manufacturing Consensus. How Companies Get Experts Onside. Conference on Integrity in Science Washington July 12<sup>th</sup>.
175. Manufacturing Consensus. American Association for the Advancement of Science Washington July 13<sup>th</sup>.
176. The Creation of Depression. American Psychological Association meeting Honolulu July 2004.
177. Birth, Ritalin, Prozac, Viagra, Death. 4S and EASST meeting Paris August 2004.
178. Manufacturing Consensus. 4S and EASST meeting Paris, August 2004
179. Suicide on Antidepressants. International Society of Pharmacoepidemiology, Bordeaux August 2004.
180. Birth, Ritalin, Prozac, Viagra, Death. In Gender and the Meaning of Mental Health, Ann Arbor, Michigan, October 2004
181. Shaping the Intimate, Culture, Brain and Development Program Hampshire College Amherst, October 2004
182. Psychopharmacology & the Government of the Self. Postgraduate Mental Health Seminar Series, Institute of Social Medicine, Rutgers University October 2004.
183. Manufacturing Consensus, The end of psychiatry as a science? International Center for the Study of Psychiatry and Psychology New York October 2004.
184. The Influence of the Pharmaceutical Industry on Psychiatry. Dept of Psychiatry, Vienna. November 2004.
185. Suicide and SSRIs. Brigham and Women's Dept of Epidemiology Boston January 2005.
186. Madness and Medication. The Third Ronnie Laing Conference, London, March 2005.
187. Birth, Ritalin, Prozac, Viagra, Death. Studium Generale Lecture Groningen April 2005
188. Intimate Psychopharmacology. The Psyences Project, Princeton University April 2005.

189. Manufacturing Consensus. Social Sources of Psychopharmacology, U of Toronto. April 2005
190. Dr Jekyll Takes an SSRI; Antidepressants and Homicide. Social Sources of Psychopharmacology, Toronto April 2005
191. Evidence Based Medicine: how it can be misused. American Psychiatric Association Annual Meeting Atlanta May 2005 Symposium 37A
192. Psychopharmacology and Government of the Self. Grey Nuns Hospital, Edmonton Alberta, May 2005
193. Schizophrenia 1900 and 2000 compared. Third Pierre Flor-Henry Lecture, Edmonton Alberta, May 2005.
194. Notes Toward a History of Mood Stabilizers. Royal College of Psychiatry Annual General Meeting, Edinburgh June 2005
195. Shaping the Intimate. Royal College of Psychiatry Annual General Meeting Edinburgh June 2005.
196. Manufacturing Consensus, Annual Invited Guest Lecture, The Priory Hospitals, London.
197. From Folie Circulaire to Bipolar Disorder, International Association for Law and Mental Health Annual Meeting Paris July 2005.
198. This house believes that evidence based medicine has debased psychiatry. North West Regional Meeting Royal College of Psychiatrists Debate with Clive Adams, Bolton Sept 2005.
199. Cognitive Enhancement: Experience with psychotropics. Sheffield Psychopathology Symposium, Sept 2005.
200. Ethics Roundtable: Hazards and Benefits of Antidepressants. Peter Gaszner, Zoltan Rihmer, Gabor Kovacs, Bela Buda, Jozsef Kovacs: Hungarian Psychopharmacology 8<sup>th</sup> Annual Meeting. Tihany October 2005.
201. Manufacturing Consensus is more important than Manufacturing Drugs. Hungarian Psychopharmacology 8<sup>th</sup> Annual Meeting. Tihany October 2005.
202. To Err is Human: To really foul up needs evidence based medicine. New Philosophies for Community Psychiatry: Recovery-Oriented, Evidence-Based, and Beyond. 8<sup>th</sup> Int Conf on Philosophy, Psychiatry and Psychology, Yale, October 2005
203. Psychopharmacology in Turmoil: a Scientific or Ethical Crisis. PET Seminars, Dept of Public Health, Columbia University New York, October 2005
204. The Root of All Evil: Money, People or Power? Canadian Association of Bioethics, Dalhousie University, October 2005

205. Psychopharmacology in Turmoil: A Scientific or Ethical Crisis. Louisiana State University Dept of Psychology & Philosophy
206. Shaping the Intimate. Chancellor's Distinguished Guest Lecture Louisiana State University, Baton Rouge, October 2005.
207. Birth, Ritalin, Prozac, Viagra and Death. Constructions of Health. U of Sydney Dept of Health Law. November 2005.
208. Antidepressants and Homicide. Medications and Criminal Justice, Institute of Criminology & U of Sydney, Dept of Health Law. November 2005
209. The Medico-Legal consequences of pharmaceutical company involvement in developing new drugs. Adverse Drug Reactions, Litigation and Drug Regulation, Sydney Bar Association, October 2005
210. The consequences of ghostwriting and lack of access to clinical trial data in the medico-legal arena. Expert evidence in Health Law. Faculty of Law University of Sydney, November 2005
211. The psychopharmacology of bipolar disorder. Welsh Psychiatric Society, Llandudno, November 2005.
212. Erasmus Prize Public Debate: Is there a crisis of scientific authority? Simon Schaffer, Steven Shapin, Josee van Eijndhoven, David Healy, Hugh Pennington. De Rode Hoed, Amsterdam November 2005
213. Psychopharmacology in Turmoil: an Ethical or Scientific Crisis. Instituto Superiore de Sanitate, Rome December 16<sup>th</sup> 2005.
214. Psychopharmacology and Modern Cultures. Australian and New Zealand Society for Psychiatry, Psychology and Law, Sydney April 3<sup>rd</sup>
215. Birth, Ritalin, Prozac, Viagra, Death, Royal Adelaide Hospital Grand Round April 4<sup>th</sup>
216. The Latest Mania, Women's & Children's Hospital Grand Round, Adelaide, April 5<sup>th</sup>
217. Suicide rates and other outcomes in Schizophrenia. Royal Adelaide Hospital psych dept internal CME, April 6<sup>th</sup>
218. Antidepressants: Suicidality, Homicidality & Efficacy. RANZCP college CME in conjunction with Healthy Skepticism, April 6<sup>th</sup> - Public Lecture.
219. Suicide rates and other outcomes in Schizophrenia. Flinders Medical Centre Psych Dept CME, April 7<sup>th</sup>
220. Antidepressants & Homicide. Australian and New Zealand Society for Psychiatry, Psychology and Law, Sydney April 8<sup>th</sup>

221. Antidepressants & Homicide. New South Wales Defence Lawyers Forum, Sydney April 10<sup>th</sup>
222. The Latest Mania. First International Conference on Disease Mongering, Plenary Lecture, Newcastle Australia, April 11<sup>th</sup>
223. Melancholia in the 19<sup>th</sup>, 20<sup>th</sup> and 21<sup>st</sup> centuries: similarities and differences. Copenhagen Dept of Psychiatry Symposium on Melancholia, May 2006
224. The New Anecdotes: Evidence Based Medicine and the Degradation of Clinical Practice and Research. In Searching for Gold Standards – the Construction and Governance of RCTs & EBM in Psychiatry. Institute of Psychiatry, June 2006.
225. Bipolar Disorder: a communal disorder. Philosophy, psychiatry and psychology, Leiden University, Holland June 2006.
226. Mood enhancement? Mood Enhancement Workshop. Maastricht, Holland, June 2006.
227. Trussed in Evidence: Guidelines, Tramlines and Faultlines. Health Action International, 25<sup>th</sup> anniversary meeting, Amsterdam, October 2006
228. Ist die Wirkung von Antidepressiva klinisch bedeutsam? Pro Hans-Juergen Moeller, and Thomas Schlaepfer, Con D Healy. Deutsche Gesellschaft fur Psychiatrie, Psychotherapie und Nervenheilkunde, Berlin, Nov 2006
229. Cargo Cult Science. In Perspectives on Scientific Practice from Science and Scientific Studies, Lorentz Center, Leiden University November 2006
230. A Pleasing Look of Truth. Public Lecture, Leiden University November 2006.
231. Global Business Masquerading as Science. The Human Laboratory. Tokyo December 2006
232. Antidepressants and Suicide. Tokyo University December 2006.
233. Antidepressants and Suicide in the Elderly. Welsh Geriatric Society, Caernarfon, March 2007.
234. Mental Health Services in North Wales. Welsh Assembly Government Meeting Caernarfon, March 2007.
235. This House believes that the UK MHRN should have access to data from studies carried out on behalf of pharmaceutical companies? Mental Health Research Network, London, April 2007.
236. Enhancing and stimulating. Second Mood Enhancement Workshop Maastricht April 28<sup>th</sup>

237. Kraepelin's impact on psychiatry. Letten Foundation Meeting Emil Kraepelin's Dichotomy. Ludwig Maximilians Universitat, Munich April 30<sup>th</sup>
238. Trussed in Evidence. UCLA, May 2007.
239. Disease Mongering. American Psychiatric Association Meeting May 2007.
240. The Use of Antidepressants for Anxiety Disorders. Consensus conference on the use of antidepressants for anxiety disorders. Comité d'évaluation des pratiques médicales en matière de médicaments. Brussels May 2007
241. Bipolar Syndrome by Proxy. Pointpark University Pittsburgh June 2007.
242. Cargo Cult Science. McGill Advanced Study Institute, Globalisation and Pharmaceuticals June 2007
243. Brand New Psychiatry. University of Western Ontario, London June 2007
244. Recovery in Psychosis. Royal College of Psychiatrists Annual Meeting Edinburgh 2007.
245. Homicide and Antidepressants. International Association for Law and Mental Health, Padua June.
246. Trussed in Evidence: Ambiguities at the interface between evidence and clinical practice. International Association for Law and Mental Health, Padua June.
247. Tracing pharmaceuticals in South Asia: Regulation, Distribution and Consumption. The Centre for International Public Health Policy. Edinburgh July 2007
248. Academic Stalking. American Psychological Association Annual Meeting San Francisco August 2007.
249. Brand Fascism. Demedicalising misery. University of East London. September 14<sup>th</sup>.
250. Growing up in a Mad World. Wellcome Collection Public Forum, London September 27<sup>th</sup>.
251. Academic Stalking. Canadian Association for University Teachers, Annual Meeting, Ottawa, November 2007.
252. Guerilla guide to mental health systems. Ethics and Mental Health, public lecture, Manchester Metropolitan University.
253. Business as usual. The triumph of pharmacology in mental health care. U of Helsinki, Dept of Sociology November 2007.
254. The Human Laboratory. Patients and the Medico-pharmaceutical complex. Mielenterveysmessut, Helsinki, November 2007



255. Swallowing it whole: this house believes that psychiatrists are unable to resist the seductive messages of the pharmaceutical industry. Institute of Psychiatry, November 2007
256. The Human Laboratory. Public Lecture, University of California, San Diego, December 2007
257. So What's the problem with Ghostwriting? European Medical Writers Association and Institute of Clinical Research, Annual Meeting – Publishing Clinical Trials: Ethics and the Pharmaceutical Industry, February 2008
258. Brand Fascism. European Molecular Biology Lab, Heidelberg April
259. Lowering Suicide Rates: Realistic or Quixotic? Association of European Psychiatrists, Nice 2008
260. Does anything stabilize moods? Royal College of Psychiatrists Annual Meeting London June 2008/
261. Antidepressants and Suicide. CINP Meeting Munich July 2008
262. Trussed in Evidence. European Molecular Biology Summer Workshop, Heidelberg, August 2008
263. Selling out or Win-win: the benefit of industry involvement on training of healthcare providers outweighs the harm? International Association of Medical Science Educators, Salt Lake City, July 2008.
264. Trussed in Evidence. European Molecular Biology Laboratories, Summer Workshop, Heidelberg, August 2008.
265. Can psychiatry play a part in reducing suicide rates? Celtic Conference Royal College of Psychiatrists, Edinburgh September 2008
266. Mania. American College of Neuropsychopharmacology Annual Meeting, Plenary Lecture, Phoenix 2008
267. How marketing created the illusion that antidepressants work. 13<sup>th</sup> National Congress of the Italian Society for Psychopathology (SOPSI) – Rome Feb 13<sup>th</sup> 2009.
268. The Future of Medical Care. Pitzer College, South California, February 2009.
269. From Jekyll and Hyde to Forensic Psychopharmacology. Patton State Hospital. February 2009.
270. The Future of Medical Care. Society and Genetics, UCLA February 2009.
271. Can Obama's Healthcare Plan Work? UCLA, March 2009.
272. Hypnotizing clinicians: the role of statistical significance testing. UCLA/NPI workshop-seminar March 2009

273. Whither Medicine? Eric Nordlander Lecture, Cornell University, New York March 2009.
274. General overview of the history of standardisation in the making and taking of psychotropic drugs. European Science Foundation Workshop on Standardizing Psychoactive Drugs and Drug Uses in the 20<sup>th</sup> Century. Utrecht April 2009.
275. Academic Stalking and Brand Fascism. York University, Toronto, Whistleblower Protection workshop, May 2009
276. The Future of Medical Care. Science and Technology Studies, Global Health Forum, University of California, Davis, May 2009.
277. Does anything stabilize moods? American Psychiatric Association Annual Meeting San Francisco May 2009
278. Psychedelic Psychopharmacotherapy: something old, something new? Royal College of Psychiatrists, Annual Meeting June 2009
279. We're all Indian Now. Tracing Pharmaceuticals in South Asia Workshop, Edinburgh, June 2009
280. Antidepressants and Violence. Broadmoor Hospital, Crowthorpe July 2009.
281. The Future of Medical Care, London Ontario, September 2009
282. Bioethical Devils and Neuroscientific Details. Halifax Bioethics Sept 2009
283. The Future of Medical Care. Grand Rounds, Dalhousie University, Sept 2009
284. The Future of Medical Care. Can Universal Healthcare Survive? University of New Brunswick, Public Lecture, Fredericton, New Brunswick, Sept 2009.
285. Hearts & Minds. Antidepressants in Pregnancy. Fredericton, New Brunswick, Sept 2009.
286. Hearts & Minds. The Risk from MotheRisk. U of Toronto, Oct 2009.
287. The Future of Medical Care. Festschrift for Ruth Kajander, U Western Ontario, London, 2009.
288. The Politics of Evidence. 5<sup>th</sup> Annual Ronald Laing Lecture. Royal College of Psychiatrists, London, October 2009.
289. Antidepressants and Birth Defects. U of Toronto, Jan 2010.
290. Conflict of Interest: The Original Sin? Debate with Arthur Schafer, U of Toronto Jan 15<sup>th</sup>.
291. The Future of Medical Care. University College London, Feb 1<sup>st</sup> 2010.

292. Hearts & Minds. Antidepressants in Pregnancy. Emory University Dept of Public Health March 2010
293. Hearts & Minds. Antidepressants in Pregnancy. Veterans Hospital Grand Rounds, UCLA, March 2010.
294. Hearts & Minds. Antidepressants in Pregnancy. Medwatcher Japan, Annual Symposium, June 2010.
295. The Wisdom of Psychopharmacology. Debate with Dilip Jeste, CINP Meeting Hong Kong 2010.
296. Pharmageddon. University of Paris, Department of Psychiatry. June 2010.
297. The Disappearance of Depression. Tristesse ou Depression, Universite Paris – Rene Descartes, Paris June 2010
298. Lessons from the History of Electroconvulsive Therapy. Royal College of Psychiatrists Annual Meeting Edinburgh 2010.
299. Data Based Medicine. American Psychological Association, Annual Meeting, San Diego, August 2010
300. Data Based Medicine v Evidence Based Medicine. Rigshospitalet Copenhagen, October 2010
301. Ghosts are in the Medical Machine. In Current Challenges in Medical Communication: Diagnosis and Curing of Unethical Practices. Polish Academy of Sciences. Warsaw October 2010
302. The End of Medical Care. Colloque on Science, Clinical Practice and Psychotropic Drugs, Free University of Bruxelles, October 2010.
303. Data Based Medicine v Evidence Based Medicine. Gent October 2010.
304. Is Medicine Terminally Ill? Mario Negri Institute Milan November 2010
305. The History of the Antidepressants: From Switzerland to Japan. The Burgholzli Hospital, Zurich November 2010.
306. The Rise and Fall of the Psychoses. Oslo University, Rikshospitalet December 2010.
307. Antipsychotics and Mental Health Legislation. Norwegian Dept of Health, December 2010.
308. Is Evidence Based Medicine the Enemy of Adverse Event Reporting. Uppsala Monitoring Centre, Uppsala Sweden, February 2011

309. The Changing Face of Psychosis. Therapeutics Initiative, Vancouver March 2011
310. The changing face of psychosis. History of Science Colloquium UCLA March 2011.
311. The changing face of psychosis. Harbor UCLA, March 2011.
312. Is Evidence Based Medicine the Enemy of Good Medical Care, Center for Health Services Research, UCLA, April 2011
313. The Mania for Bipolar Disorder, University of Wisconsin, Milwaukee April 2011.
314. Is Evidence Based Medicine the Enemy of Good Medical Care, Center for Health Services Research, Harbor UCLA, May 2011
315. Ghosts in the Machine. University of Toronto Faculty of Law Meeting on Ghostwriting. May 2011
316. Threats from restrictions to the dissemination of the results of scientific research. In Threats to the Universities, Humanities and Science Conference, London Cambridge July 2011
317. Has Evidence Based Medicine become the problem it was designed to solve. Dunedin School of Medicine, Public Lecture – Department of Bioethics, Sept 2011.
318. The Eclipse of Medical Care. Royal New Zealand College of General Practitioners Annual Meeting Sept 2011.
319. Antidepressants and Suicide. Sponsored by Casper, Auckland Sept 11.
320. The Cardinals of Psychiatry, Health Action International Meeting, Cork Sept 2011.
321. Making Markets. American Association of Anthropology Annual Meeting November 2011
322. Lets have more conflicts of interest. The Scottish Mental Health Research Network. December 2011
323. The Eclipse of Medical Care. Lancaster University Management School – Feb 2012.
324. From Mania to Bipolar Disorder. Lyon. France 2012
325. The Money in Mania. Studium Generale Lecture, Gent, February 2012
326. Hiding the Bodies. Radical Statistics, London, February 2012
327. Quality Prescribing. North Staffordshire Annual Meeting of Non-Medical Prescribers

328. The Changing Face of Psychosis. Tufts University, Boston March 2012.
329. The Psychology of Drugs and Risk. Rutgers University , New Jersey March 2012.
330. The Changing Face of Psychosis. Rutgers University, New Jersey, March 2012
331. The Psychology of Drugs and Risk. City University New York March 2012.
332. The Eclipse of Medical Care. College of Pharmacy U of Toronto March 2012.
333. The Eclipse of Medical Care. McMaster University March 2012.
334. The Psychology of Drugs and Risk, Commonwealth Club San Francisco
335. Antidepressants and Pregnancy, Harbor UCLA March 2012
336. The Changing Face of Psychosis, VA UCLA, March 2012
337. The Psychology of Drugs and Risk. Providence Tarzana UCLA Medical Center March 2012.
338. Professional Suicide? Royal College of Psychiatrists Annual Meeting June 2012.
339. Professional Suicide. APA's Institute of Psychiatric Services Meeting New York, October 2012.
340. Changing Face of Psychosis. Plenary Lecture. APA's Institute of Psychiatric Services Meeting New York, October 2012.
341. The power of the pharmaceutical industry over healthcare. 13<sup>th</sup> Annual Interdisciplinary Research Conference, Trinity College Dublin November
342. RCTs: A gold standard method for hiding adverse events. DUAG symposium, Copenhagen, November 2012
343. The Eclipse of Medicine, American Medical Student Association, Rush University, February 2013.
344. Antidepressants and Homicide. Kent College of Law, Chicago, February 2013
345. Antidepressants and Violence, University of Illinois Chicago, February 2013.
346. Scaremongering: How RxISK will keep us all safe. Selling Sickness, Washington DC February 2013
347. The efficacy of antidepressants. APA annual meeting San Francisco May 2013.
348. Do controlled trials work? Welsh-Breton Psychiatrists Meeting, Dinard June 2013

349. The man who changed psychiatry and the day it changed. Welsh-Breton Psychiatrists Meeting, Dinard June 2013
350. The Creation of Knowledge in Medicine. University of Insubria, Faculty of Medicine Annual Guest Lecture July 2013
351. The Impact of Drugs on Dimensional Aspects of Personality. XIII International Congress on Disorders of Personality, Copenhagen September
352. Antidepressants and the Politics of Health, Portcullis House, All-Party Group on Involuntary Tranquilizer Addiction.
353. Antidepressants and the Politics of Health. Health and Wellbeing Public Lecture Series IV, Bangor University, Llandudno October 2013.
354. Do Antidepressants work? Presidential Debate with Irving Kirsch, Hans-Jurgen Moeller and Elias Erikson Annual DGGPN meeting Berlin November.
355. The Open Society and Drug Transparency. The Open Society, Berlin November
356. The Shipwreck of the Singular. Is Evidence Based Medicine bad for Medicine. St Bartholomew's Global Health Week.
357. Slow Medicine. Centre for Bioethics & Culture, The Sind Institute, Bioethics Seminar – Karachi December
358. The Changing Face of Psychosis, Aga Khan University, Dept of Psychiatry Karachi, December
359. Study 329 and Access to Clinical Trial Data. Agenas, Rome December
360. RCTs as an Act of Authorship. Annual Cochrane Meeting, Napoli, December
361. The Shipwreck of the Singular. Madrid Mental Health Association, February 2014
362. When does my opinion count? Annual Non-Medical Prescriber Meeting, Stafford.
363. Study 329 and Access to Clinical Trial data. Dept of Bioethics. Dalhousie Bioethics Visiting Professorship, March 2014
364. Slow Medicine. Department of Pharmacy and Bioethics. Dalhousie Bioethics Visiting Professorship, March 2014
365. Academic Stalking and Wikipedia Trolling. Dept of Radiology Grand Rounds Dalhousie Bioethics Visiting Professorship, March 2014
366. The Shipwreck of the Singular. Public Lecture. Dalhousie Bioethics Visiting Professorship, March 2014

367. Commercialization and its effects on Academic Medicine. Dept of Bioethics Workshop. Dalhousie Bioethics Visiting Professorship, March 2014
368. Study 329 and Access to Clinical Trial Data. Northern Ireland Medico-Legal Society Annual Meeting, Belfast. March 2014
369. Slow Medicine, Trieste Department of Pharmacology and Psychiatry, April 2014.
370. Do Antidepressants work? The Scandinavian Society for Psychopharmacology, April 2014
371. How adverse events can improve clinical practice and advance research. The Mario Negri Institute Milan. April
372. Madness Incorporated: Debate with Richard Bentall and Dinesh Bhugra. How the Light Gets In. Hay-on-Wye Literary Festival, May
373. Docs in the Dock. Debate with Clare Gerada and Gisella Stuart. How the Light Gets In. Hay-on-Wye Literary Festival, May
374. The Persecution of Heretics. How the Light Gets In. Hay-on-Wye Literary Festival, May
375. The role of evidence in clinical practice. European Orthopaedics Meeting London June 2014
376. Authority in Biomedicine, Department of History of Science, UCLA, November
377. Die on Your Feet. International Society for Ethical Psychology and Psychiatry, UCLA November 2014
378. Authorship and Authority in Medicine. Rutgers University November 2014.
379. Die on Your Feet or Live on Your Knees: What does Recovery Mean? FEMHC Conference, Yale University, April 2015
380. Violence & Antidepressants: New Medico-Legal Issues. Medico-Legal Society Meeting of Ireland. Dublin May 2015.
381. Positive Thinking and the Name Game. How the Light Gets In Festival. Hay-on-Wye, Debate with Dinesh Bhugra & Harvi Carel, May 24, 2015.
382. Are Hospitals Bad For Us? How the Light Gets In Festival. Hay-on-Wye, Debate with Natalie Bennett, Diane Abbott, & Mark Salter, May 24, 2015.
383. When the Drugs Don't Work. How the Light Gets In Festival. Hay-on-Wye, May 25, 2015.
384. Balance in Healthcare in On Balance: Lifestyle, Health and WellBeing. Exeter University Department of History, June 25<sup>th</sup> 2015.

385. Strengths and Limitations of Surveillance methods for Adverse Effects. MHRA Expert Working Group on Hormone Based Pregnancy Tests, London December 4<sup>th</sup> 2015.
386. Some Questions for NICE. Improving Access to Psychological Therapies Annual General Meeting, London, Feb 3<sup>rd</sup> 2016.
387. Can Medical Science be Trusted if its Authors are Ghosts, Ryerson University Toronto, March 17<sup>th</sup> 2016.
388. Managing the Side Effects of Antidepressants. Hospital Medicine Treating Depression Meeting, March 24<sup>th</sup> London.
389. The Danger Industry. How the Light Gets In, Hay-on-Wye May 2016.
390. Is Science Authoritative? St George's Hospital, Grand Rounds, September 2016, London
391. Medicine: Caught Between Law and Science. Willis G. Cunningham Lecture in Law and Medicine Queens' University, Kingston, September 28<sup>th</sup> 2016
392. Psychopharmacology. The British Neuropsychiatric Association, 30<sup>th</sup> Anniversary Meeting, London February 22<sup>nd</sup> 2017
393. A Call to Harms. WHO Meeting Trieste Italy November 2017
394. Safety or Efficacy: Which is more Important? Staffordshire, Non-Medical Prescribers, Annual Meeting, November 2017.
395. A Call to Harms. Students Global Health Annual Meeting Aberdeen, February 2018.
396. The Politics of Neuroscience, King's College London Neurosciences Forum, February 2018
397. Minds, Madness and Medicine; How the Light Gets In Festival. Hay on Wye. May
398. Sex Lies and Pharmacology; How the Light Gets In Festival. Hay on Wye. May.
399. Your Life in the Balance. How the Light Gets In Festival. Hay on Wye. May 2018
400. Failing Health Systems and What we can do about them. Exeter U June 2018
401. The Closing of the Psychiatric Mind. International Symposium Epistemology, Psychopathology and Neurosciences, Sao Paulo Brazil, June 2018
402. Making Medicines Safer for all of us, TedX Talk Aberystwyth, Nov 2018
403. The Greatest Failure in Medicine. Welsh Senate Symposium on Prescription Drug Dependence December 2018



404. A Call to Harms, Lincoln Mental Health Services February 2019
405. Brave New World, London School of Economics March 2019
406. Health Care and Health Systems, Maastricht University March 2019
407. AI in Healthcare: Debate. How the Light Gets In. London, Sept 2019.
408. Potential Solutions to Post-Licensing Problems. Improving the detection, analysis and reporting of harms in medicines Exploring, Enhancing and Empowering in Erice Sicily (4Es forum). October 2019
409. Enduring Sexual Dysfunction following Antidepressants. International Society of Drugs Bulletins Paris October
410. A Pill for Neo-Liberalism. Faculty of Journalism. University of Grenoble, October 2019.
411. A Pill for Neo-Liberalism. Faculty of Psychiatry, Vinatier Hospital, Lyons, October 2019.
412. Study 329. Faculty of Psychiatry, Vinatier Hospital, Lyons, October 2019.
413. Does my Bias look Big in This? Mad in America Webinar Series May 2019.
414. The Problems with Randomized Controlled Trials. Harveian Society Annual Guest Lecture May 2020.
415. The Evidence behind the use of Medicines. University College London Jan 5<sup>th</sup> 2021. <https://www.youtube.com/watch?v=uLxT54Fhguw&t=29s>.
416. Sex and Evidence Based Medicine. Therapeutics Initiative Methods Seminar Series, February 2021.
417. Antidepressants and Dependence. Medicating Normal Outreach Webinar May 14<sup>th</sup>. 2021 London.
418. Psychiatric Drugs: Post Withdrawal Syndromes. Mad in America, Webinar Series May 15<sup>th</sup> 2021. <https://youtu.be/XB77kMdoNBs>
419. Antidepressants, Sexual Dysfunction and Medical Groupthink. Medicating Normal Outreach, June 9<sup>th</sup> 2021.
420. Post-SSRI (PSSD) Sexual Dysfunction: History and Relevance. International Society for Sexual Medicine, July 29<sup>th</sup> 2021.
421. The Standardization of Psychiatry. Mind, State and Society, Royal Society of Medicine October 5<sup>th</sup> 2021.

- 422. "L'enquête déclinée en fiction, à l'ère des essais cliniques truqués" Journalism and Medicine. Grenoble University Workshop, October 11 2021.
- 423. Where Does the Misinformation Come From? Queen Mary University of London Symposium Dec 6<sup>th</sup>
- 424. Physicist quizzes doctor re science in medicine. Bournemouth Dec 9<sup>th</sup>
- 425. SSRIs and Global Health. World Council for Health, London Dec 13<sup>th</sup>
- 426. Who's Afraid of Science. New Mexico Technical Institute Feb 2022.
- 427. Reducing Medication Burden is now a Privilege of Wealth. Grand Rounds, North York General Hospital November 2022.
- 428. Standardizing Psychiatry and its Clinicians. Grand Rounds, Mount Sinai Hospital, New York, January 2023.
- 429. Beware Doctors Bearing Gifts. Invited Public Lecture University of Lethbridge Alberta Jan 2023.
- 430. The Dark Side of Clinical Trials. The Devon and Exeter Medical Society, February 2023.
- 431. Faulty Evidence and Moral Hazard, Brigham Hospital Law and Medicine Group Forum February 2023.

**Video:**

CPD Online website: <http://www.psychiatrycpd.co.uk/default.aspx?page=28660>

## **WEBSITES & BLOGS**

Linked to the publication of *Let Them Eat Prozac* in 2003 I set up a website [HealyProzac.com](http://HealyProzac.com) to make available a raft of documents, primarily linked to the Fentress and Forsyth homicide and suicide cases that were referenced in the book. This site also hosted material on the topic of academic stalking – how someone attempting to draw attention to treatment related adverse events can run into difficulties and risks losing their employment. The site contained material on ghost-writing also.

In February 2012 I set up a blog - [DavidHealy.org](http://DavidHealy.org). This was aimed at preparing the way for the opening of [RxISK.org](http://RxISK.org). [DavidHealy.org](http://DavidHealy.org) has since had 280 posts, approximately 450,000 words, on topics primarily linked to the creation of medical knowledge, the duties of doctors, and the role of medicine today.

In late 2012, [RxISK.org](http://RxISK.org) launched. [RxISK](http://RxISK.org) makes available all FDA data on adverse events from 2004 onwards, along with Canadian adverse event data and data posted to [RxISK](http://RxISK.org). The primary aims are to inform people about the safety profile of the treatment they are taking, to offer them a chance to report adverse event data, to give them an assessment as to the likelihood that their adverse event is linked to the treatment they are taking in a report they can take to their doctor in the hope that the earliest possible intervention might reduce the risks of a treatment going wrong.

The [RxISK.org](http://RxISK.org) site also has a blog and to date there have been 215 posts, with approximately 360,000 words. These have primarily covered accounts of the nature of and impact of adverse effects of a range of treatments. Between [davidhealy.org](http://davidhealy.org) and [RxISK.org](http://RxISK.org) there have been over 800,000 words spread over 2000 pages.

In 2014, [Study329.org](http://Study329.org) was launched. This site makes available a vast array of documents linked to the SSRIs and suicide controversy from the 1980s through to the present day, in particular as this has affected children and led to Black Box Warnings for suicide risks on antidepressants. The site hosts many of the key media programs that have helped shape the debate as well as the story of how Study 329 came to Restored and the difficulties in attempting to get it published in the *BMJ*.

In 2016, with colleagues I launched [MadnessofNorthWales](http://MadnessofNorthWales). This site is dedicated to the history of mental illness and mental health services in North Wales. It makes available 50 years of mental health records of patients entering the old Asylum between 1875 and 1924 and also offers contemporary data between 1994 and 2010 allowing us to show the changing incidence of various disorders and the responses to treatment. It is a unique facility. There is nothing like it anywhere else. The hope is in treating mental illness and the issues surrounding it in an intensely local way we can shed light on a global story.

## **Workshop/Training Programmes**

When psychopharmacology goes wrong. Leading Edge Seminars, Toronto May 2002.

What a therapist needs to know about psychopharmacology. Centre for Training in Psychotherapy, April 23<sup>rd</sup> 2005, Toronto

When psychopharmacotherapy goes wrong. Leading Edge Seminars, Toronto, April 26<sup>th</sup> 2005

One of its outcomes was both the same. Statistical Methods in Psychopharmacology, Welsh Psychiatric Society, November 2005

Antidepressants & Homicide, RANZAPPL, Hunter Valley, April 10-11<sup>th</sup> 2006

How to recognise and deal with the hazards of psychotropic medication.  
Open Doors, U West of England, Bristol, February 27 2009.

The Marketing of Psychotropic Drugs, University of Minneapolis, May 2009.

I have also lectured in Departmental & Regional forums in Bradford, Bristol (x3), Cardiff (x 12), Cambridge (x4), Dumfries, Edinburgh (x2), Wrexham (x2), Glasgow, Leicester, Leeds, Maastricht, Newcastle (x3), Northampton, Norwich, Oxford, Sheffield, St Bartholomew's, The Clarke Institute Toronto (x4), The Institute of Psychiatry (x3), a number of Irish departmental settings, on general practice training schemes in North Wales, Royal College of Psychiatrists membership schemes in a number of locations, & on several occasions to the Welsh Psychiatric Society.

I have lectured in a variety of pharmaceutical company sponsored meetings throughout the UK (Newcastle, Glasgow, Cardiff, Bournemouth, Cambridge (x3), Merseyside (x3), London (x3)), as well as in Denmark, Greece (x2), Finland, Italy, Portugal, Spain (x2), Sweden, South Africa & at Satellite Symposia at major meetings such as ECNP & BAP.

These lectures have been on the history of the antidepressants or antipsychotics or on aspects of the methodologies for evaluating psychotropic efficacy and adverse effects of treatment.

I have lectured on a number of occasions for patient groups and for other professionals allied to mental health. Lectures to patient groups have included 3 annual guest lectures for MIND in North Wales.

I have presented in forums such as the Café Scientifique in Leeds in 1999, 2002, and 2012, as well as for the British Association for the Advancement of Science, Imperial College, Sept 2000.

I have been consulted on a range of programmes dealing with psychotropic drugs including File on Four, Panorama, Channel 4's The Secret History of Drugs, & Discovery TVs The Psychopharmacological Era, as well as CBC television and radio in Canada, including the Fifth Estate. I have also participated in a nationally broadcast debate on Australia's All in the Mind radio programme on issues surrounding the contemporary use of antidepressants, and participated in ABC in the US 20-20 and CBS programmes on hazards linked to the use of antidepressants.

## **SYMPOSIA & MEETINGS ORGANISED**

I have organised Symposia for BAP Annual Meetings:

- In 1991 on Dementia: Biological Bases
- & Altered Consciousness: Phenomenology and Pharmacology
- In 1992 on: The Circadian System and Affective Disorders
- In 1993 on: Beyond the Receptor: The Significance of Gene Expression for Psychopharmacology
- In 1995 on: Social Phobia.
- In 1996 on: The Psychopharmacology of Aggression
- In 1997 on: Compliance and Psychopharmacology
- In 2000 on: Suicide and Psychotropic Treatment.
- In 2005 on: Dependence & Psychotropic Agents

The North Wales Regional Meeting of the BAP Spring 1992:

- Psychopharmacology: Big Business or Successful Science.
- Psychopharmacology in Primary Care

The BAP Winter Meeting 1993

- Psychotropic Drug Development: Social, Economic & Clinical Issues

A BAP Round-Table on Paediatric Psychopharmacology - London Jan 1997.

- This was attended by an international experts, regulators, the Royal Coll Psychiatrists and the pharmaceutical industry. I organised the meeting and wrote the resulting consensus statement.

For the Royal College of Psychiatrists (RCP)

- I have organised a 1-day meeting & publication of proceedings in Sept 1989, on : History of Biological Psychiatry
- & Symposia for the RCP, Winter Meeting in Glasgow 1995 on: The Relations between Psychiatry and the Pharmaceutical Industry
- & for the Joint RCP & Assoc European Psychiatrists meeting in London 1996 on The History of Physical Treatments in Psychiatry
- & a symposium for the 1998 CINP meeting in Glasgow on: Neuropsychopharmacology: The Historical Record.
- & for the Joint Royal College & World Psychiatric Assoc meeting in London 2001 on: The History of Drug Dependence

For the Int Assoc of Law & Mental Health:

- When medical and legal worlds collide: SSRIs homicide and suicide Paris 2005
- Homicide and Psychotropic Drugs: Padua 2007.

For the World Psychiatric Association Annual Meeting in Buenos Aires Sept 2011 on :  
The Historiography of Mental Illness

## **FORMAL TEACHING**

In Galway, I taught on pharmacological and psychiatric topics in lecture, seminar and tutorial formats.

In Cambridge I gave lectures, tutorials and clinics to medical students and on MRCPsych courses - covering schizophrenia, affective disorders, psychopharmacology, substance abuse and the management and assessment of dementia. I was Asst. Tutor to Dr G Berrios for the MRCPsych and was involved in organising and assessing psychiatric and medical student training.

In N Wales, I train medical students from Cardiff and Liverpool, post-graduate psychiatric and GP trainees and contribute to paramedical training.

I have an Honorary appointment with the Dept. of Psychology in Bangor, where from 1990 to 1997 I lectured on abnormal psychology and the history of psychiatry.

I contribute to the College of Medicine's Diploma in Therapeutics, organised by Prof. Philip Routledge.

From 1990 to 2001, I organised a weekly multidisciplinary post-graduate training slot in Bangor with input from national and international guest lecturers.

From 1995 to the present I have organised an annual Guest Lecture slot with contributions from Edward Shorter, Richard Dawkins, Anthony Clare, Roy Porter, Simon Wessely, David Weatherall, David Goldberg & others.

I have lectured on the MRCPsych course for the U of Liverpool from 1997 to 2005.

I organised and taught the psychopharmacology module for the U of Birmingham's Diploma in Community Mental Health, while this was being offered.

From 1992 through to the end of 1997, I was the S.R/Sp.R Programme Director in North Wales. During this time, the rotation expanded from three A.M.I and one learning disability post to seven A.M.I and old age posts, one clinical lecturer post, two learning disability posts and there was always at least one research senior registrar.

I have been the N Wales representative on the All-Wales Speciality Training Committee through the process of Calmanisation.

I was also the Audit Convenor in Gwynedd and the medical representative on the Clinical Effectiveness Committee from 1994 to 2001.

## **DOCTORAL THESES SUPERVISED:**

North West Wales has had no medical student and no formal post-graduate medical training during the period of time that I have been there. There have, furthermore, been no formal arrangements for collaborative research between the College of Medicine and the University of Wales Bangor.

Trainees on the psychiatric training scheme do not choose North Wales for research purposes. There have nevertheless been a relatively high number of trainees who have their names on articles and small though the numbers are there has been a greater proportion of trainees who have gone on to undertake higher research degrees than can be readily found elsewhere.

Dr C F Fear, MD. Cognitive Processes in Obsessive-Compulsive and Delusional Disorders. Awarded August 1995.

Dr B Williams, PhD. The Role of the Person in People Centred Mental Health Care. Awarded. November 1995.

Dr M-A Pasteur, PhD. The Role of Monoamine systems in Memory Functioning. Awarded. November 1995.

Dr R Tranter, PhD, The Role of Personality in Depressive Disorders and their Response to Antidepressants. Awarded December 2008

Tarang Sharma, University of Copenhagen, Adverse Effects of Antidepressants and their Effects on the Quality of Life of Patients

Shubha Srinivasan, Bangor University, Emotional Processing in Mood Disorders

I currently have 2 whole-time research scientists working with me and I am supervising Paul Green & Margaret Harris in PhD programmes.

I have been an external PhD thesis examiner for:

University of London - psychiatry

University of London – psychology

University of New South Wales - history and philosophy of science

Lampeter University - philosophy of science

Brighton University – medical sociology

Copenhagen University – medical sociology

As well as external examiner for final MB exams at St Bartholomew's Hospital 1996-98.

& external examiner on the Aston University's Distance Learning Psychiatric Pharmacy Diploma & Certificate from 2002 – 2005.

#### **INDUSTRIAL CONSULTANCIES:**

Astra-Zeneca

Boots Pharmaceuticals

Eli Lilly

Janssen Pharmaceuticals

Lundbeck

Organon

Pharmacia-Upjohn

Rhone-Poulenc Rorer

SmithKline Beecham

## LEGAL CASES: 2022

### Trial

|                 |            |                     |      |
|-----------------|------------|---------------------|------|
| Forsyth D       | Prozac     | Suicide Homicide    | 1999 |
| Tobin D         | Paxil      | Suicide Homicide    | 2001 |
| Comer (UK)      | Prozac     | Assault             | 2003 |
| Kilker D        | Paxil      | Birth Defects       | 2009 |
| Novopharm (Can) | Zyprexa    | Patent              | 2010 |
| Torrence        | Zoloft     | Malpractice Suicide | 2010 |
| Dolin D         | Paxil      | Suicide             | 2017 |
| McCarthy        | Risperdal  | Malpractice Suicide | 2021 |
| Kiy-Adonai (UK) | Paroxetine | Homicide – Tribunal | 2018 |

D = Daubert Hearing; F = Frye

### Trial Criminal

|               |            |          |      |
|---------------|------------|----------|------|
| Houston (UK)  | Paxil      | Assault  | 2003 |
| Pitman (US)   | Zoloft     | Homicide | 2005 |
| Langley (UK)  | Citalopram | Assault  | 2015 |
| Holmes (US)   | Sertraline | Homicide | 2015 |
| Nijhawan (UK) | Sertraline | Homicide | 2021 |

### Inquests and Other Hearings

|                |             |                  |      |
|----------------|-------------|------------------|------|
| Clancy (IRL)   | Celexa      | Suicide/Homicide | 2009 |
| Woodley (UK)   | Celexa      | Suicide          | 2010 |
| Bradshaw (AUS) | Risperidone | Suicide          | 2014 |
| O'Neill (UK)   | Zoloft      | Suicide          | 2019 |

### Daubert/Frye Hearings

|            |        |         |      |
|------------|--------|---------|------|
| Berman F/D | Prozac | Suicide | 2001 |
| Cassidy D  | Prozac | Suicide | 2003 |
| Miller D   | Zoloft | Suicide | 2000 |
| Ilich D    | Celexa | Suicide | 2014 |

### Report & Deposition

|            |        |         |      |
|------------|--------|---------|------|
| Berman F/D | Prozac | Suicide | 2001 |
| Cassidy D  | Prozac | Suicide | 2003 |
| Lown,      | Prozac | Suicide | 2002 |
| Prior      | Prozac | Suicide |      |
| Blowers    | Prozac | Suicide |      |
| Miller D   | Zoloft | Suicide | 2000 |
| Motus      | Zoloft | Suicide | 2001 |
| Witczak    | Zoloft | Suicide | 2005 |
| Torrence   | Zoloft | Suicide | 2010 |
| Coburn     | Paxil  | Suicide | 2001 |
| Tucker,    | Paxil  | Suicide | 2006 |
| Van Dyke,  | Paxil  | Suicide | 2007 |
| Turek      | Paxil  | Suicide | 2007 |
| Collins    | Paxil  | Suicide | 2007 |
| Kohler     | Paxil  | Suicide | 2009 |
| Thompson   | Paxil  | Suicide | 2009 |



|                       |                    |                           |      |
|-----------------------|--------------------|---------------------------|------|
| In Re Paxil           | Paxil              | Dependence                | 2005 |
| Ebel                  | Zyprexa            | Suicide                   | 2007 |
| Moote                 | Zyprexa            | Suicide                   | 2010 |
| Forest Securities     | Celexa             | Securities                | 2007 |
| In Re Celexa          | Celexa             | Suicide                   | 2012 |
|                       | Lexapro            |                           |      |
| Krivicich             | Celexa             | Suicide                   | 2014 |
| Ilich D               | Celexa             | Suicide                   | 2014 |
| Ackerman              | Efexor             | Suicide                   | 2006 |
| Ham                   | Isosorbide         | Suicide                   | 2018 |
| Novak                 | Paxil              | Birth Defect              | 2010 |
| Kuykendall            | Lexapro            | Birth Defects             | 2014 |
| Foster                | Zoloft             | Birth Defects             | 2014 |
| Niemann               | Lexapro            | Birth Defects             | 2015 |
| Goulet                | Zoloft             | Birth Defects             | 2015 |
| Porter                | Zoloft             | Birth Defects             | 2015 |
| Lindsay (UK)          | Prozac             | Suicide                   | 2002 |
| Bartram et al (Can)   | Paxil              | Birth Defect Class Action | 2016 |
| Singh et al (Can)     | Paxil              | Birth Defect Class Action | 2017 |
| Price et al (Can)     | Celexa             | Birth Defect Class Action | 2017 |
| Newman (UK)           | Malpractice Celexa | Suicidality               | 2018 |
| Richardson (Idaho)    | Prozac             | Suicidality               | 2022 |
| <b>Criminal Cases</b> |                    |                           |      |
| Pierre (UK)           | Prozac             | Assault                   | 2000 |
| Hawkins (Aus)         | Zoloft             | Homicide                  | 2001 |
| Bentley (Aus)         | Efexor             | Attempted Homicide        | 2004 |
| Rule (UK)             | Celexa             | Homicide                  | 2010 |
| Baymiller (US)        | Paxil              | Homicide                  | 2010 |
| Fields (US - Mixed)   | Efexor             | Homicide                  | 2010 |
| O'Brien (UK)          | Efexor             | Armed Robbery             | 2015 |
| Holmes (US)           | Zoloft             | Homicide                  | 2015 |
| Stones (UK – Neg)     | Zoloft             | Homicide                  | 2015 |
| Zaman (UK - Neg)      | Celexa             | Homicide                  | 2015 |
| Danysh (US)           | Prozac             | Homicide                  | 2015 |
| Kiy-Adonai (UK)       | Paxil              | Homicide                  | 2018 |
| Carmichael (Can)      | Paxil              | Homicide                  | 2018 |
| Lemak (US)            | Zoloft             | Homicide                  | 2021 |
| Dawson (UK)           | Celexa             | Fraud                     | 2012 |
| Benitez (US)          | Cocktail           | Sex Molestation           | 2014 |
| Cox (US)              | Montelukast        | Sex Molestation           | 2015 |
| Kelly (UK)            | Paroxetine         | Public Nuisance           | 2015 |
| Marshall (UK)         | Celexa             | Sexual Abuse              | 2018 |

### Other Cases

|                    |             |            |      |
|--------------------|-------------|------------|------|
| NHS (UK)           | LSD x 50    | Harms      | 2002 |
| NHS (UK)           | ECT x 2     | Harms      | 2005 |
| McCraw             | Paxil       | ASD        | 2015 |
| Bailey et al v GSK | Paxil       | Dependence | 2019 |
| Cutland (UK)       | Doxycycline | Suicide    | 2020 |
| Morgan (UK)        | Citalopram  | Suicide    | 2020 |
| Connell (IRL)      | Doxycycline | Suicide    | 2021 |
| Short (US)         | Sertraline  | Homicide   | 2021 |

### Registration Board Hearings/Inquests

|                |                      |                       |      |
|----------------|----------------------|-----------------------|------|
| GMC (UK)       | Fitness to Practice  | (Paxton v Buckley)    | 2003 |
| Torrence (US)  | Malpractice          | Suicide               | 2010 |
| Bradshaw (AUS) | Inquest/ Malpractice | Case Ref: 2009/471819 | 2010 |
| Hughes (AUS)   | Fitness to Practice  |                       | 2018 |

### Patent Exploration

|                |              |  |      |
|----------------|--------------|--|------|
| Novopharm      | Zyprexa      |  | 2008 |
| Fineberg (Can) | Aripiprazole |  | 2016 |
| Fineberg (Can) | Lurasidone   |  | 2021 |

### Amicus Brief

|       |                      |                         |      |
|-------|----------------------|-------------------------|------|
| Short | Park Nicollet Clinic | Minnesota Supreme Court | 2022 |
|-------|----------------------|-------------------------|------|

### Clemency Hearing

|       |        |                     |      |
|-------|--------|---------------------|------|
| Lemak | Zoloft | Homicide - Illinois | 2022 |
|-------|--------|---------------------|------|